id,conversation_id,created_at,date,time,timezone,user_id,username,name,place,tweet,language,mentions,urls,photos,replies_count,retweets_count,likes_count,hashtags,cashtags,link,retweet,quote_url,video,thumbnail,near,geo,source,user_rt_id,user_rt,retweet_id,reply_to,retweet_date,translate,trans_src,trans_dest
1209080009895424001,1209080009895424001,2019-12-23 17:25:12 IST,2019-12-23,17:25:12,+0530,785531131366109184,micheldoepke,Michel Doepke,,$SGMO Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment $PFE  https://t.co/nohR9rxQHa,en,[],['https://www.businesswire.com/news/home/20191223005185/en/'],[],1,12,27,[],"['sgmo', 'pfe']",https://twitter.com/MichelDoepke/status/1209080009895424001,False,,0,,,,,,,,[],,,,
1209000916818501632,1209000916818501632,2019-12-23 12:10:55 IST,2019-12-23,12:10:55,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,roche $SRPT deal: ...revisiting the $PFE transcript from back then:  Pfizer might want to go $SGMO #DMD now finaly ? (Sangamo said they have the #DMD sulution ready in the fridge already)  https://t.co/NBdkHtjV8G,en,[],[],['https://pbs.twimg.com/media/EMc7xS6WsAAZNcd.jpg'],1,6,8,"['dmd', 'dmd']","['srpt', 'pfe', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/1209000916818501632,False,,1,https://pbs.twimg.com/media/EMc7xS6WsAAZNcd.jpg,,,,,,,[],,,,
1206904170894286848,1206903715220856832,2019-12-17 17:19:12 IST,2019-12-17,17:19:12,+0530,3426014292,semodough,dough,,"IND transfer to $PFE  for SB-525 hemophilia gene therapy is substantially completed; Pfizer is advancing SB-525 into a Phase 3 registrational study in 2020 also introducing new gene therapy genome regulation programs for addressing highly prevalent diseases,with IND targets 2021",en,[],[],[],1,1,10,[],['pfe'],https://twitter.com/semodough/status/1206904170894286848,False,,0,,,,,,,,[],,,,
1206783830939635713,1206783830939635713,2019-12-17 09:21:00 IST,2019-12-17,09:21:00,+0530,627498274,dividendhawk,DH,,Pfizer (PFE) Increased Their Dividend by 5.6%  https://t.co/AMTOOM2lSX via @MoreDividends,en,"[{'screen_name': 'moredividends', 'name': 'jason from moredividends', 'id': '743807151441797121'}]",['https://buff.ly/2EljDgG'],[],0,2,6,[],[],https://twitter.com/DividendHawk/status/1206783830939635713,False,,0,,,,,,,,[],,,,
1206774349522460672,1206774349522460672,2019-12-17 08:43:20 IST,2019-12-17,08:43:20,+0530,2499229069,dvdnddiplomats,Dividend Diplomats,,"Pfizer increased their dividend 5.5% today while BA maintained their current dividend.   Not too surprised with BA's announcement, especially given the bad 737-MAX news.    But as a $PFE shareholder, I'm excited!    https://t.co/zjvAxa02I9",en,[],['https://www.dividenddiplomats.com/expected-dividend-increases-in-december-2019/'],[],3,2,16,[],['pfe'],https://twitter.com/DvdndDiplomats/status/1206774349522460672,False,,0,,,,,,,,[],,,,
1206587634132377606,1206587634132377606,2019-12-16 20:21:23 IST,2019-12-16,20:21:23,+0530,2723696479,dividendhike,dividend hike,,#Pfizer just hiked its dividend for the 10th consecutive year with a 5.8 percent increase to $0.38 quarterly. $PFE #dividends #correction :D  https://t.co/wUkjsTMbx9,en,[],[],['https://pbs.twimg.com/media/EL6pDqYWoAASqd3.png'],1,5,28,"['pfizer', 'dividends', 'correction']",['pfe'],https://twitter.com/dividendhike/status/1206587634132377606,False,,1,https://pbs.twimg.com/media/EL6pDqYWoAASqd3.png,,,,,,,[],,,,
1206248123246534657,1206248123246534657,2019-12-15 21:52:18 IST,2019-12-15,21:52:18,+0530,2499229069,dvdnddiplomats,Dividend Diplomats,,Pfizer $PFE and Boeing $BA YOU'RE UP NEXT!  I am betting Pfizer does a $0.02 increase per quarter or 5.56% and Boeing does a $0.05 increase per quarter.  Just 2 names for the...Expected Dividend Increases - December 2019  #Dividends #Invest #Money #Coffee  https://t.co/zjvAxa02I9,en,[],['https://www.dividenddiplomats.com/expected-dividend-increases-in-december-2019/'],[],3,0,8,"['dividends', 'invest', 'money', 'coffee']","['pfe', 'ba']",https://twitter.com/DvdndDiplomats/status/1206248123246534657,False,,0,,,,,,,,[],,,,
1204900959614189568,1204900959614189568,2019-12-12 04:39:09 IST,2019-12-12,04:39:09,+0530,22446818,ianlopuch,Ian Lopuch,,"Someone on my personal Facebook talked smack about my beloved $PFE. CEO pay, this &amp; that. They are no longer my friend. As a shareholder, thank you @pfizer for allowing me to #invest in medical innovation &amp; bettering society‚Äôs health. Much love! ‚ù§Ô∏è (Disclosure: I am long PFE)",en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}]",[],[],6,0,39,['invest'],['pfe'],https://twitter.com/ianlopuch/status/1204900959614189568,False,,0,,,,,,,,[],,,,
1203931181127020549,1203931181127020549,2019-12-09 12:25:36 IST,2019-12-09,12:25:36,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,Credit Suisse $BMRN Sangamo/Pfizer‚Äôs SB-525 (Hemophilia A Gene Therapy) Continues to Look Viable we think this update is encouraging and suggests $SGMO $PFE SB-525 may be a strong contender among hem A gene therapies in development.,en,[],[],[],0,7,12,[],"['bmrn', 'sgmo', 'pfe']",https://twitter.com/_B_I_O_T_E_C_H_/status/1203931181127020549,False,,0,,,,,,,,[],,,,
1203820177512706053,1203820177512706053,2019-12-09 05:04:30 IST,2019-12-09,05:04:30,+0530,35789155,fwpharma,FirstWord Pharma,,"Pfizer, Sangamo's haemophilia A gene therapy SB-525 continues to show sustained increased FVIII levels  https://t.co/uO3gIs0E5N $PFE $SGMO #ASH19",en,[],['https://www.firstwordpharma.com/node/1686240'],[],0,3,11,['ash19'],"['pfe', 'sgmo']",https://twitter.com/fwpharma/status/1203820177512706053,False,,0,,,,,,,,[],,,,
1203488504862380033,1203488504862380033,2019-12-08 07:06:33 IST,2019-12-08,07:06:33,+0530,809065245876645888,stock_truth,StockTrooth,,$PFE Pfizer‚Äôs DMD gene therapy safety data revealed a decrease in C3 proteins. Here‚Äôs why:   $SRPT $SLDB  https://t.co/kJmKY8iStT,en,[],[],[],1,3,15,[],"['pfe', 'srpt', 'sldb']",https://twitter.com/Stock_Truth/status/1203488504862380033,False,,1,https://pbs.twimg.com/ext_tw_video_thumb/1203488465163296768/pu/img/7Q7rM6YgLz90r1gj.jpg,,,,,,,[],,,,
1203487797916688386,1203487797916688386,2019-12-08 07:03:45 IST,2019-12-08,07:03:45,+0530,809065245876645888,stock_truth,StockTrooth,,$PFE Pfizer DMD gene therapy safety data revealed an increase in C5B-C9 proteins relating to compliment activation... here‚Äôs what those proteins do:  $SRPT $SLDB  https://t.co/bsMo9x1PLj,en,[],[],[],1,4,20,[],"['pfe', 'srpt', 'sldb']",https://twitter.com/Stock_Truth/status/1203487797916688386,False,,1,https://pbs.twimg.com/ext_tw_video_thumb/1203487755633909761/pu/img/2eN4sp7v74IY-KgN.jpg,,,,,,,[],,,,
1203375239679361025,1203375239679361025,2019-12-07 23:36:29 IST,2019-12-07,23:36:29,+0530,4496252499,persimmonti,Persimmon Tree Investments,,"$SGMO $PFE #ASH19   SB-525 looking quite good, and it‚Äôs great that Pfizer is in charge:  https://t.co/nfUHwgZQxe",en,[],[],['https://pbs.twimg.com/media/ELM_ZseW4AUZ2GR.jpg'],0,4,7,['ash19'],"['sgmo', 'pfe']",https://twitter.com/PersimmonTI/status/1203375239679361025,False,,1,https://pbs.twimg.com/media/ELM_ZseW4AUZ2GR.jpg,,,,,,,[],,,,
1202675210606010368,1202675210606010368,2019-12-06 01:14:49 IST,2019-12-06,01:14:49,+0530,42814585,jaredshopkins,Jared S. Hopkins,,"$PFE CEO Albert Bourla says during #Forbeshealth panel that Pfizer products should be described as ""medicines"" -- not ""assets."" ... ""We're not accountants.""",en,[],[],[],1,1,7,['forbeshealth'],['pfe'],https://twitter.com/JaredSHopkins/status/1202675210606010368,False,,0,,,,,,,,[],,,,
1199660320782004224,1199660320782004224,2019-11-27 17:34:43 IST,2019-11-27,17:34:43,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"$PFE Pfizer, $NVS Novartis lead pharma spending spree on gene therapy production 11 biotechs invest $2 bln in gene therapy production  * Firms cite rising costs, delays at contract manufacturers  * FDA focusing on manufacturing consistency  https://t.co/2nHIx0XDfd",en,[],['https://www.reuters.com/article/genetherapy-novartis/focus-pfizer-novartis-lead-pharma-spending-spree-on-gene-therapy-production-idUSL1N28500V'],[],1,5,6,[],"['pfe', 'nvs']",https://twitter.com/_B_I_O_T_E_C_H_/status/1199660320782004224,False,,0,,,,,,,,[],,,,
1198589346431094784,1198589346431094784,2019-11-24 18:39:03 IST,2019-11-24,18:39:03,+0530,1130525203619037185,11graphs,11Graphs,,(1/8) Most profitable top 25 largest US #stocks by EBITDA Margin: 1. üá∫üá∏ VISA $V: 70.2% 2. üá∫üá∏ MASTERCARD $MA: 56.3% 3. üá∫üá∏ PFIZER $PFE: 49.1% 4. üá∫üá∏ MICROSOFT $MSFT: 46.6% 5. üá∫üá∏ INTEL $INTC: 46.1%  https://t.co/A022FlQUNI,de,[],[],['https://pbs.twimg.com/media/EKI-prEXkAUMOMA.png'],1,13,42,['stocks'],"['v', 'ma', 'pfe', 'msft', 'intc']",https://twitter.com/11Graphs/status/1198589346431094784,False,,1,https://pbs.twimg.com/media/EKI-prEXkAUMOMA.png,,,,,,,[],,,,
1197584325245652997,1197584325245652997,2019-11-22 00:05:27 IST,2019-11-22,00:05:27,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,$SGMO comments on $PFE partnership and says #Pfizer CEO spoke this week about how this is an asset they havent expected it to be as good as it is #Hemophila A #ASH19 $BMRN $ONCE  https://t.co/sv2jQGU7tQ,en,[],[],[],3,10,19,"['pfizer', 'hemophila', 'ash19']","['sgmo', 'pfe', 'bmrn', 'once']",https://twitter.com/_B_I_O_T_E_C_H_/status/1197584325245652997,False,,1,https://pbs.twimg.com/ext_tw_video_thumb/1197584053916119041/pu/img/rEQ2ZYQJFGD211Fu.jpg,,,,,,,[],,,,
1196797156130271235,1196797156130271235,2019-11-19 19:57:32 IST,2019-11-19,19:57:32,+0530,15563814,loftus,Peter Loftus,,You don't see this too often. Docs who served as investigators on Pfizer $PFE studies of tafamidis publicly blast high price,en,[],[],[],2,3,13,[],['pfe'],https://twitter.com/Loftus/status/1196797156130271235,False,https://twitter.com/RobertLangreth/status/1196793751093628929,0,,,,,,,,[],,,,
1193764983248752640,1193764983248752640,2019-11-11 11:08:45 IST,2019-11-11,11:08:45,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,JPMorgan had the opportunity to meet with $PFE mgmt team including CEO .@AlbertBourla Pfizer highlighted number of underappreciated assets: #genetherapy development program including #Hemophilia A with $SGMO focused on bolt-on M&amp;A partnerships (eg $GILD / $GLPG type structures)  https://t.co/WfTVSQ3vcl,en,"[{'screen_name': 'albertbourla', 'name': 'albertbourla', 'id': '1154781658933006337'}]",[],['https://pbs.twimg.com/media/EJEa1zdWoAINGoq.jpg'],0,13,24,"['genetherapy', 'hemophilia']","['pfe', 'sgmo', 'gild', 'glpg']",https://twitter.com/_B_I_O_T_E_C_H_/status/1193764983248752640,False,,1,https://pbs.twimg.com/media/EJEa1zdWoAINGoq.jpg,,,,,,,[],,,,
1192081609706688512,1192081609706688512,2019-11-06 19:39:38 IST,2019-11-06,19:39:38,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"$SGMO  ‚ÄúWe are pleased with the progress of the program toward a registrational Phase 3 study led by $PFE Pfizer, who announced it has enrolled its first patient in the 6-month Phase 3 lead-in study #ASH19 #ASH2019",en,[],[],[],0,5,19,"['ash19', 'ash2019']","['sgmo', 'pfe']",https://twitter.com/_B_I_O_T_E_C_H_/status/1192081609706688512,False,,0,,,,,,,,[],,,,
1189173438818242560,1189173438818242560,2019-10-29 19:03:36 IST,2019-10-29,19:03:36,+0530,3426014292,semodough,dough,,"HCW $SGMO SB-525 Creeping up on Valrox $PFE 3Q19 update with insights into SB-525.await 26 to 52 week follow-up data from ongoing Phase 1/2 program of SB-525 in Hemophilia A during 4Q19, partner Pfizer has initiated enrollment of subjects into the lead-in, observational segment",en,[],[],[],1,4,14,[],"['sgmo', 'pfe']",https://twitter.com/semodough/status/1189173438818242560,False,,0,,,,,,,,[],,,,
1189166256026456069,1189166256026456069,2019-10-29 18:35:03 IST,2019-10-29,18:35:03,+0530,1278852289,tradingnation,Trading Nation,,Check out shares of Pfizer on the rise after the drugmaker beat the street‚Äôs earnings estimates and raised full-year guidance $PFE  https://t.co/6OqChbEcVW,en,[],[],['https://pbs.twimg.com/media/EIDEZ94WoAADi6V.jpg'],0,2,5,[],['pfe'],https://twitter.com/TradingNation/status/1189166256026456069,False,,1,https://pbs.twimg.com/media/EIDEZ94WoAADi6V.jpg,,,,,,,[],,,,
1189163349524860929,1189163349524860929,2019-10-29 18:23:30 IST,2019-10-29,18:23:30,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,$SGMO SB-525 Creeping up on Valrox $BMRN  $PFE Pfizer's 3Q19 update with insights into SB-525.  https://t.co/O7O4kCJrrl,en,[],[],['https://pbs.twimg.com/media/EIDBv32W4AE-aIa.jpg'],0,9,16,[],"['sgmo', 'bmrn', 'pfe']",https://twitter.com/_B_I_O_T_E_C_H_/status/1189163349524860929,False,,1,https://pbs.twimg.com/media/EIDBv32W4AE-aIa.jpg,,,,,,,[],,,,
1189140532452159491,1189140532452159491,2019-10-29 16:52:50 IST,2019-10-29,16:52:50,+0530,913260122004086784,kessanman,Á±≥ÂõΩÊ†™ Ê±∫ÁÆó„Éû„É≥,,„Éï„Ç°„Ç§„Ç∂„ÉºÊ±∫ÁÆó Pfizer (NYSE:PFE) Q3'19 EPS(Non-GAAP) $0.75 ‰∫àÊÉ≥Ôºã$0.13 Â£≤‰∏ä $12.68B (-4.6% Y/Y) ‰∫àÊÉ≥Ôºã$420M  Ë£ΩËñ¨Â§ßÊâã„ÄÇ„Ç¨„Ç§„ÉÄ„É≥„Çπ‰∏äÊñπ‰øÆÊ≠£(Ê∑ª‰ªòÂõ≥ÂèÇÁÖß)  Ê†™‰æ°„ÅØÊôÇÈñìÂ§ñ„Åß+3.1% („ÉÄ„Ç¶ÊßãÊàê‰ºÅÊ•≠)  https://t.co/byuhKrfdUi  https://t.co/9LYGjhMmez,ja,[],['https://s21.q4cdn.com/317678438/files/doc_financials/2019/q3/Q3-2019-Earnings-Charts-FINAL.pdf'],['https://pbs.twimg.com/media/EICs_YMVUAAm1BM.png'],0,17,72,[],[],https://twitter.com/KessanMan/status/1189140532452159491,False,,1,https://pbs.twimg.com/media/EICs_YMVUAAm1BM.png,,,,,,,[],,,,
1189134760129552385,1189134760129552385,2019-10-29 16:29:54 IST,2019-10-29,16:29:54,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"Dr. Albert Bourla, $PFE Pfizer Chief Executive Officer, stated ‚ÄúWe continue to be excited with the progress we are making with our pipeline,... We began enrolling patients in a #Phase3 study of PF-07055480 (#SB525 $SGMO ), an investigational gene therapy approach for hemophilia A",en,[],[],[],0,8,20,"['phase3', 'sb525']","['pfe', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/1189134760129552385,False,,0,,,,,,,,[],,,,
1189133652585787392,1189133652585787392,2019-10-29 16:25:30 IST,2019-10-29,16:25:30,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"$PFE says In October 2019, based on the results observed in the ongoing Phase 1/2 study of investigational PF-07055480 gene therapy for severe #hemophilia A,  Pfizer #began #enrollment in a lead-in #Phase3 study $SGMO $$$  https://t.co/zc88zjRXsy",en,[],[],['https://pbs.twimg.com/media/EICmv0TXUAEhdag.jpg'],0,12,24,"['hemophilia', 'began', 'enrollment', 'phase3']","['pfe', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/1189133652585787392,False,,1,https://pbs.twimg.com/media/EICmv0TXUAEhdag.jpg,,,,,,,[],,,,
1188898729249652736,1188898729249652736,2019-10-29 00:52:00 IST,2019-10-29,00:52:00,+0530,26368450,pearlf,Pearl Freier,,Our goal is to provide a digital companion to all of our medicines - Pfizer  EVP &amp; Chief Digital &amp; Technology Officer Lidia Fonseca #HLTH2019 h/t @mmaskaly $PFE,en,"[{'screen_name': 'mmaskaly', 'name': 'michelle maskaly', 'id': '16379971'}]",[],[],0,1,6,['hlth2019'],['pfe'],https://twitter.com/PearlF/status/1188898729249652736,False,,0,,,,,,,,[],,,,
1183486777081905154,1183486777081905154,2019-10-14 02:26:50 IST,2019-10-14,02:26:50,+0530,102754598,johncendpts,John Carroll,,Pfizer takes aim at a flagship franchise at Sanofi and Regeneron ‚Äî and scores a few direct hits $PFE $SNY $REGN $LLY  https://t.co/Ao6lOCXtQJ,en,[],['https://endpts.com/pfizer-takes-aim-at-a-flagship-franchise-at-sanofi-and-regeneron-and-scores-a-few-direct-hits/'],[],0,1,6,[],"['pfe', 'sny', 'regn', 'lly']",https://twitter.com/JohnCendpts/status/1183486777081905154,False,,0,,,,,,,,[],,,,
1178703268932800512,1178703268932800512,2019-09-30 21:38:53 IST,2019-09-30,21:38:53,+0530,102754598,johncendpts,John Carroll,,"So $NVS and $LLY both now have significantly better OS data on CDK 4/6 than $PFE's blockbuster Ibrance. If Pfizer was truly primarily interested in patients, shouldn't they restrict use of their drug? Discuss --  https://t.co/ATEhWrZrVw",en,[],['https://endpts.com/novartis-eli-lilly-marquee-positive-survival-data-for-cdk-4-6-franchises-but-can-they-actually-beat-pfizers-blockbuster/'],[],5,0,9,[],"['nvs', 'lly', 'pfe']",https://twitter.com/JohnCendpts/status/1178703268932800512,False,,0,,,,,,,,[],,,,
1177629238607929346,1177629238607929346,2019-09-27 22:31:04 IST,2019-09-27,22:31:04,+0530,26368450,pearlf,Pearl Freier,,"Pfizer announced they have extended their oncology collaboration with @flatironhealth to ""increase the use of real-world data in Pfizer‚Äôs development of innovative targeted cancer medicines."" The collaboration first began in 2014  https://t.co/jCOzsDRWhd $PFE",en,"[{'screen_name': 'flatironhealth', 'name': 'flatiron health', 'id': '604969770'}]",['https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_flatiron_health_announce_expanded_strategic_collaboration_to_unlock_power_of_real_world_evidence_in_oncology'],[],0,2,10,[],['pfe'],https://twitter.com/PearlF/status/1177629238607929346,False,,0,,,,,,,,[],,,,
1174185529199472641,1174185529199472641,2019-09-18 10:27:00 IST,2019-09-18,10:27:00,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,Cowen first page of $PFE Pfizer report: Key pipeline products include abrocitinib (JAK1i) in Phase III for AD; #SB525 (with $SGMO Sangamo) #genetherapy for hemophilia A in Phase II;  and 20v pneumococcal vaccine (in Phase III) read-outs will be key to multiple expansion  https://t.co/5eacD5pHlO,en,[],[],['https://pbs.twimg.com/media/EEuLRqCX4AQHVcl.jpg'],1,6,13,"['sb525', 'genetherapy']","['pfe', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/1174185529199472641,False,,1,https://pbs.twimg.com/media/EEuLRqCX4AQHVcl.jpg,,,,,,,[],,,,
1171637308413661185,1171637308413661185,2019-09-11 09:41:16 IST,2019-09-11,09:41:16,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,"$SGMO ex CFO ""The great thing about @Pfizer meeting of Phase 3 manufacturing for Hem-A is that it's easily replicable to other gene therapy programs in the future. We don't expect a huge amount of redo in the scale of process"" $PFE response: $500M build up  https://t.co/t18OhbqqEl",en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}]",['https://www.investorvillage.com/smbd.asp?mb=1933&mn=133273&pt=msg&mid=19773748'],[],0,0,4,[],"['sgmo', 'pfe']",https://twitter.com/Biotech2050/status/1171637308413661185,False,,0,,,,,,,,[],,,,
1171286840642588673,1171286840642588673,2019-09-10 10:28:38 IST,2019-09-10,10:28:38,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"$PFE says at Morgan Stanley Areas of interest for M&amp;A include  oncology, inflammation and immunology, internal medicine, rare disease, and vaccines.  Pfizer is not considering mega deals.",en,[],[],[],1,4,5,[],['pfe'],https://twitter.com/_B_I_O_T_E_C_H_/status/1171286840642588673,False,,0,,,,,,,,[],,,,
1171254971498663936,1171254971498663936,2019-09-10 08:22:00 IST,2019-09-10,08:22:00,+0530,3460109487,endpts,Endpoints News,,"Tony Coles sets sail on new neuro pursuit at #Cerevel, steering Pfizer spinout as CEO  https://t.co/m1XrhT6tTm $PFE",en,[],['https://endpts.com/tony-coles-sets-sail-on-new-neuro-pursuit-at-cerevel-steering-pfizer-spinout-as-ceo/'],[],0,6,15,['cerevel'],['pfe'],https://twitter.com/endpts/status/1171254971498663936,False,,0,,,,,,,,[],,,,
1169221753278816256,1169221753278816256,2019-09-04 17:42:43 IST,2019-09-04,17:42:43,+0530,26368450,pearlf,Pearl Freier,,Very interesting profile of Pfizer's Chief Scientific Officer Mikael Dolsten by @matthewherper. Includes examination of his 10 yr tenure &amp; how PFE's productivity compares to other pharmas. Includes comments from experts @bhmunos &amp; @John_LaMattina  https://t.co/rUqdxs0rUj $PFE,en,"[{'screen_name': 'matthewherper', 'name': 'matthew herper', 'id': '44438256'}, {'screen_name': 'bhmunos', 'name': 'bernard munos', 'id': '30618682'}, {'screen_name': 'john_lamattina', 'name': 'john lamattina', 'id': '295221061'}]",['http://bit.ly/2ktCiAp'],[],0,4,11,[],['pfe'],https://twitter.com/PearlF/status/1169221753278816256,False,,0,,,,,,,,[],,,,
1169211287106138112,1169211287106138112,2019-09-04 17:01:08 IST,2019-09-04,17:01:08,+0530,44438256,matthewherper,Matthew Herper,,"I'll be tweeting more about this $PFE piece later this AM (it really covers 20 years of company history). Anybody have any questions about the plan for a new, slimmer Pfizer?  https://t.co/MSIswM6r8E  Going to have tea now.",en,[],['https://www.statnews.com/2019/09/04/pfizers-chessmaster-how-a-top-scientist-helped-invigorate-a-lumbering-drug-giant/'],[],6,8,16,[],['pfe'],https://twitter.com/matthewherper/status/1169211287106138112,False,,0,,,,,,,,[],,,,
1164236384347000833,1164236384347000833,2019-08-21 23:32:39 IST,2019-08-21,23:32:39,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,"$CRSP up 1% and $SGMO down 1% on the news below wherein @Pfizer is going full blast in #genetherapy  (Spoiler alert: $PFE teamed up with @SangamoTx for gene therapy, stunned with the results in #hemophilia &amp; RMAT designation and not interested in #CRISPR)  #ThisIsNotAJoke",en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'sangamotx', 'name': 'sangamo therapeutics', 'id': '809083633671643136'}]",[],[],0,3,9,"['genetherapy', 'hemophilia', 'crispr', 'thisisnotajoke']","['crsp', 'sgmo', 'pfe']",https://twitter.com/Biotech2050/status/1164236384347000833,False,https://twitter.com/JohnCendpts/status/1164175702557646848,0,,,,,,,,[],,,,
1164197317425160192,1164175702557646848,2019-08-21 20:57:24 IST,2019-08-21,20:57:24,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,"@JohnCendpts ""We‚Äôre going to be a leading player in gene therapy,‚Äù says Bob Smith, the SVP for global gene therapy at @pfizer. And this is what it takes as the pharma giant scoops up more acquisitions and collaborations in the gene therapy world."" Can $PFE do that without $SGMO Don't think so",en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}]",[],[],0,3,9,[],"['pfe', 'sgmo']",https://twitter.com/Biotech2050/status/1164197317425160192,False,,0,,,,,,,,"[{'screen_name': 'JohnCendpts', 'name': 'John Carroll', 'id': '102754598'}]",,,,
1164176440935493633,1164176440935493633,2019-08-21 19:34:27 IST,2019-08-21,19:34:27,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"$PFE Pfizer Invests Half Billion Dollars to Advance State-of-the-Art #Gene #Therapy Facility in Sanford, North Carolina $SGMO Hemophilia A ie , ready for more #Fabry #DMD  https://t.co/FwpNeFO4xL",en,[],['https://www.businesswire.com/news/home/20190821005406/en/Pfizer-Invests-Billion-Dollars-Advance-State-of-the-Art-Gene'],[],0,4,8,"['gene', 'therapy', 'fabry', 'dmd']","['pfe', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/1164176440935493633,False,,0,,,,,,,,[],,,,
1164048735833399296,1164048735833399296,2019-08-21 11:07:00 IST,2019-08-21,11:07:00,+0530,3460109487,endpts,Endpoints News,,"Pfizer Foundation offers $2M in grants to #NGOs tackling antimicrobial resistance; Biogen, Invitae join forces to develop faster #SMA diagnostic  https://t.co/XB5Rcpappt $PFE $BIIB $NVTA",en,[],['https://endpts.com/pfizer-foundation-offers-2m-in-grants-to-ngos-tackling-antimicrobial-resistance-biogen-invitae-join-forces-to-develop-faster-sma-diagnostic/'],[],0,0,6,"['ngos', 'sma']","['pfe', 'biib', 'nvta']",https://twitter.com/endpts/status/1164048735833399296,False,,0,,,,,,,,[],,,,
1161751321592172545,1161751321592172545,2019-08-15 02:57:54 IST,2019-08-15,02:57:54,+0530,958404261628469250,mysterytrader99,Mystery Trader,,Daily $PFE : *New Chart!*  #PFE literally skydiving at terminal velocity for weeks. Green VBP support is logical bounce zone at 32.50.  If that does not hold then damage could be irreparable. Only one word to describe it: #Ugly   #Pfizer #Pharmaceutical #medication #medicine  https://t.co/4nFvvXE1cN,en,[],[],['https://pbs.twimg.com/media/EB9eqqsXoAMrLOw.jpg'],2,2,20,"['pfe', 'ugly', 'pfizer', 'pharmaceutical', 'medication', 'medicine']",['pfe'],https://twitter.com/MysteryTrader99/status/1161751321592172545,False,,1,https://pbs.twimg.com/media/EB9eqqsXoAMrLOw.jpg,,,,,,,[],,,,
1159813130861654021,1159813130861654021,2019-08-09 18:36:13 IST,2019-08-09,18:36:13,+0530,758386485846544384,realwillmeade,Will Meade,,"If uwant to bottom fish trading options, only trade bull call spreads with time behind it. You actually make money on the time expiration, bc your selling a call. Pfizer $PFE looks like a nice bottom fish üé£. $PFE September $40/41 call spreads and it has a free money gap fill.  https://t.co/bj4FfwLsr4",en,[],[],['https://pbs.twimg.com/media/EBh74szWkAEMO5u.jpg'],0,5,23,[],"['pfe', 'pfe']",https://twitter.com/realwillmeade/status/1159813130861654021,False,,1,https://pbs.twimg.com/media/EBh74szWkAEMO5u.jpg,,,,,,,[],,,,
1159486240284127234,1159486240284127234,2019-08-08 20:57:16 IST,2019-08-08,20:57:16,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,#BREAKING                                                                                            $PFE Pfizer just implemented $SGMO SB525 in existing Spark trial   https://t.co/pJ3YwMJeUa,de,[],['https://www.investorvillage.com/smbd.asp?mb=1933&mn=131568&pt=msg&mid=19667200'],[],2,12,23,['breaking'],"['pfe', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/1159486240284127234,False,,0,,,,,,,,[],,,,
1157381914199777280,1157381914199777280,2019-08-03 01:35:26 IST,2019-08-03,01:35:26,+0530,4788946161,ra_fun,ra fun üá∫üá∏,,FANTASTIC script growth of Vascepa:  $AMRN #VASCEPA #AMRN @Amarincorp #ATH  FYI @Novartis $NVS @pfizer $PFE  https://t.co/69h34gM0Ca,en,"[{'screen_name': 'amarincorp', 'name': 'amarin', 'id': '2892097336'}, {'screen_name': 'novartis', 'name': 'novartis', 'id': '17226612'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}]",[],"['https://pbs.twimg.com/media/EA_YsYBXkAAJy4A.jpg', 'https://pbs.twimg.com/media/EA_YsvcXYAE59Zx.jpg', 'https://pbs.twimg.com/media/EA_YtE4XoAIjwCt.jpg', 'https://pbs.twimg.com/media/EA_YthPXkAQkNWk.jpg']",1,8,20,"['vascepa', 'amrn', 'ath']","['amrn', 'nvs', 'pfe']",https://twitter.com/ra_fun/status/1157381914199777280,False,,1,https://pbs.twimg.com/media/EA_YsYBXkAAJy4A.jpg,,,,,,,[],,,,
1156883231196626944,1156883231196626944,2019-08-01 16:33:50 IST,2019-08-01,16:33:50,+0530,2808025947,pharmacompass,PharmaCompass,,Why Pfizer &amp; Mylan's endeavor to build a global generic powerhouse needs to be seen in light of Daiichi‚Äôs disastrous acquisition of Ranbaxy  https://t.co/3Y46tAu0z4 @d_s_thakur @VikasReports @KatherineEban #BottleofLies $pfe $myl,en,"[{'screen_name': 'd_s_thakur', 'name': 'dinesh s. thakur', 'id': '1173286656'}, {'screen_name': 'vikasreports', 'name': 'vikas dandekar', 'id': '29193745'}, {'screen_name': 'katherineeban', 'name': 'katherine eban', 'id': '26849735'}]",['https://www.pharmacompass.com/radio-compass-blog/compliance-to-determine-the-success-of-mylan-s-merger-with-pfizer-s-upjohn'],[],0,6,8,['bottleoflies'],"['pfe', 'myl']",https://twitter.com/pharmacompass/status/1156883231196626944,False,,0,,,,,,,,[],,,,
1156297605120450565,1156297605120450565,2019-07-31 01:46:46 IST,2019-07-31,01:46:46,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,So $SGMO #genetherapy manufacturing to be done by $PFE and #CellTherapy manufacturing to be done by $GILD Great partners @SangamoTx @GileadSciences @pfizer @BoisselStephane,en,"[{'screen_name': 'sangamotx', 'name': 'sangamo therapeutics', 'id': '809083633671643136'}, {'screen_name': 'gileadsciences', 'name': 'gilead sciences', 'id': '309728693'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'boisselstephane', 'name': 'stephane boissel', 'id': '2580053524'}]",[],[],0,3,6,"['genetherapy', 'celltherapy']","['sgmo', 'pfe', 'gild']",https://twitter.com/Biotech2050/status/1156297605120450565,False,https://twitter.com/Biotech2050/status/1156296870408392705,0,,,,,,,,[],,,,
1156225912913977345,1156225912913977345,2019-07-30 21:01:53 IST,2019-07-30,21:01:53,+0530,2182414804,don_crisse,Cristofer,,"#Pfizer √§r likt en klon av #JNJ g√§llande utdelning. Dock h√∂gre skuld. Med dagens nedg√•ng i #PFE √§r DA = 3,65 %, vilket ocks√• √§r snitt f√∂r de senaste 3, 5 resp. 10 √•ren. P/E √§r idag ca 22 &amp; snittet f√∂r 5 √•r --&gt; 24,1. 10 √•r --&gt; 21,5. Finns mer att s√§ga, men √§r nedg√•ngen ""k√∂pv√§rd""?",sv,[],[],[],1,0,12,"['pfizer', 'jnj', 'pfe']",[],https://twitter.com/don_crisse/status/1156225912913977345,False,,0,,,,,,,,[],,,,
1156000830132146177,1156000830132146177,2019-07-30 06:07:30 IST,2019-07-30,06:07:30,+0530,2494284157,tradingjustice,Trading Justice,,"$PFE S&amp;P downgrades Pfizer by to AA-minus. As mentioned previously, #Pfizer has been very resilient to selloffs in 2019 and potential technical support zones exist at $39 and $35. With earnings now behind us, Pfizer will become attractive at lower levels for Boomerang Trades.  https://t.co/nTyhtkDaHt",en,[],[],['https://pbs.twimg.com/media/EArwoHvUYAAfM4Z.jpg'],1,1,7,['pfizer'],['pfe'],https://twitter.com/tradingjustice/status/1156000830132146177,False,,1,https://pbs.twimg.com/media/EArwoHvUYAAfM4Z.jpg,,,,,,,[],,,,
1155868577511215105,1155868577511215105,2019-07-29 21:21:58 IST,2019-07-29,21:21:58,+0530,102094857,adamfeuerstein,Adam Feuerstein,,The Pfizer-Mylan deal is not quite as it appears  https://t.co/3p4reAgKcZ via @matthewherper $MYL $PFE,en,"[{'screen_name': 'matthewherper', 'name': 'matthew herper', 'id': '44438256'}]",['https://www.statnews.com/2019/07/29/the-pfizer-mylan-deal-is-not-quite-as-it-appears/'],[],2,6,11,[],"['myl', 'pfe']",https://twitter.com/adamfeuerstein/status/1155868577511215105,False,,0,,,,,,,,[],,,,
1155867974445797376,1155867974445797376,2019-07-29 21:19:34 IST,2019-07-29,21:19:34,+0530,44438256,matthewherper,Matthew Herper,,My take on $PFE-$MYL: The Pfizer-Mylan deal is not quite as it appears  https://t.co/iuSgyi3Tcr via,en,[],['https://www.statnews.com/2019/07/29/the-pfizer-mylan-deal-is-not-quite-as-it-appears/'],[],4,4,6,[],['pfe'],https://twitter.com/matthewherper/status/1155867974445797376,False,,0,,,,,,,,[],,,,
1155852943175892997,1155852943175892997,2019-07-29 20:19:51 IST,2019-07-29,20:19:51,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,$pfe PFIZER REPORTS SECOND-QUARTER 2019 RESULTS highlights $sgmo hemophilia A no mention of Spark $once in release  https://t.co/wANxzkfkEF,en,[],[],['https://pbs.twimg.com/media/EApqHmZXYAAxg2n.jpg'],0,4,10,[],"['pfe', 'sgmo', 'once']",https://twitter.com/_B_I_O_T_E_C_H_/status/1155852943175892997,False,,1,https://pbs.twimg.com/media/EApqHmZXYAAxg2n.jpg,,,,,,,[],,,,
1155835461836976129,1155835461836976129,2019-07-29 19:10:23 IST,2019-07-29,19:10:23,+0530,497262990,jchatterleycnn,Julia Chatterley,,"Very generic -- Pfizer spinning off its generic drug unit, tying up with EpiPen maker, Mylan. @MattEganCNN joins @firstmove to break down the details. $PFE $MYL  https://t.co/dBbu3dhHHQ",en,"[{'screen_name': 'mattegancnn', 'name': 'matt egan', 'id': '1080306914'}, {'screen_name': 'firstmove', 'name': 'first move cnn', 'id': '1036631333433421824'}]",[],[],0,11,39,[],"['pfe', 'myl']",https://twitter.com/jchatterleyCNN/status/1155835461836976129,False,,1,https://pbs.twimg.com/amplify_video_thumb/1155835161411559424/img/mE0QU7Nc_itEO3lU.jpg,,,,,,,[],,,,
1155832497227390977,1155832497227390977,2019-07-29 18:58:36 IST,2019-07-29,18:58:36,+0530,223589965,gantosj,Joe,,"$PFE Pfizer ""aims"" to enroll approx. 12 boys with DMD who are ambulatory &amp; aged 5 to 12 Parents who attend PPMD on 06/28 &amp; saw $PFE data &amp; SAEs, will think 5 times before let their kid get PFE GT &amp;see him declining back after a year. And PREVENT him from getting $SRPT GT later on",en,[],[],[],2,0,16,[],"['pfe', 'pfe', 'srpt']",https://twitter.com/GantosJ/status/1155832497227390977,False,https://twitter.com/GantosJ/status/1142138030595219456,0,,,,,,,,[],,,,
1155829430519861253,1155829430519861253,2019-07-29 18:46:25 IST,2019-07-29,18:46:25,+0530,40273633,4awesometweet,Reminiscences of an American Capitalist,,"Market Preview:   Futures flat Pfizer - Mylan Combination  President criticizes Fed (Again) üëá ""The E.U. and China will further lower interest rates and pump money into their systems ...   To be continued ... üòâ  @DiMartinoBooth @jennablan  $pfe #fed",en,"[{'screen_name': 'dimartinobooth', 'name': 'danielle dimartino booth', 'id': '3280573716'}, {'screen_name': 'jennablan', 'name': 'jennifer ablan', 'id': '110302086'}]",[],[],2,5,11,['fed'],['pfe'],https://twitter.com/4Awesometweet/status/1155829430519861253,False,,0,,,,,,,,[],,,,
1155817442666528768,1155817442666528768,2019-07-29 17:58:47 IST,2019-07-29,17:58:47,+0530,131655202,gschoenstein,George W. Schoenstein üöÄ‚úàÔ∏èüìà‚òÅÔ∏è,,"Pfizer, the world‚Äôs largest drugmaker, plans to combine its off-patent drug business  with generic-drug maker Mylan and form a #NewCo. Under the agreement, each Mylan share would be converted into one share of the NewCo. $MYL up 13% in premarket.  https://t.co/9WFaaIPj16 $PFE  https://t.co/TpZIPb1lFQ",en,[],['https://buff.ly/2Yphwjy'],['https://pbs.twimg.com/media/EApJ1sbW4AA-apt.jpg'],0,13,13,['newco'],"['myl', 'pfe']",https://twitter.com/gschoenstein/status/1155817442666528768,False,,1,https://pbs.twimg.com/media/EApJ1sbW4AA-apt.jpg,,,,,,,[],,,,
1155810577631076352,1155810577631076352,2019-07-29 17:31:30 IST,2019-07-29,17:31:30,+0530,44438256,matthewherper,Matthew Herper,,Breaking up Pfizer only took 8 years. $PFE $MYL  https://t.co/VRNLQDT7rc,en,[],['https://www.forbes.com/sites/matthewherper/2011/05/01/pfizers-radical-surgery/'],[],1,3,10,[],"['pfe', 'myl']",https://twitter.com/matthewherper/status/1155810577631076352,False,,0,,,,,,,,[],,,,
1155798034589970433,1155798034589970433,2019-07-29 16:41:39 IST,2019-07-29,16:41:39,+0530,913260122004086784,kessanman,Á±≥ÂõΩÊ†™ Ê±∫ÁÆó„Éû„É≥,,„Éï„Ç°„Ç§„Ç∂„ÉºÊ±∫ÁÆó Pfizer (NYSE:PFE) Q2'19 EPS(Non-GAAP) $0.80 ‰∫àÊÉ≥ +$0.05 Â£≤‰∏ä $13.26B (-1.6% Y/Y) ‰∫àÊÉ≥ -$160M  FY2019„Ç¨„Ç§„ÉÄ„É≥„Çπ Â£≤‰∏ä $50.5ÔΩû$52.5B (ÂæìÊù• $52ÔΩû$54B) EPS(Non-GAAP) $2.76ÔΩû$2.86 (ÂæìÊù• $2.83ÔΩû$2.93)  ÁâπË®±Âàá„ÇåÂåªËñ¨ÂìÅ‰∫ãÊ•≠„Çí„Éû„Ç§„É©„É≥„Å®Áµ±Âêà„Åô„ÇãË®àÁîªÁô∫Ë°®  https://t.co/sp9eTpuDB9  https://t.co/6i3JcjwrYk,ja,[],['https://s21.q4cdn.com/317678438/files/doc_financials/Quarterly/2019/q2/Q2-2019-Earnings-Charts-FINAL.pdf'],"['https://pbs.twimg.com/media/EAo37YmUcAcelA1.jpg', 'https://pbs.twimg.com/media/EAo38KeUIAYv375.jpg', 'https://pbs.twimg.com/media/EAo389TUwAEH6QV.jpg', 'https://pbs.twimg.com/media/EAo39jNUYAEiqhB.jpg']",1,18,47,[],[],https://twitter.com/KessanMan/status/1155798034589970433,False,,1,https://pbs.twimg.com/media/EAo37YmUcAcelA1.jpg,,,,,,,[],,,,
1155793014511558656,1155793014511558656,2019-07-29 16:21:42 IST,2019-07-29,16:21:42,+0530,404422077,squawkcnbc,Squawk Box,,Pfizer to combine off-patent drug business with Mylan $PFE $MYL   @megtirrell reports on the details:  https://t.co/PRktM3tVKt,en,"[{'screen_name': 'megtirrell', 'name': 'meg tirrell', 'id': '47678782'}]",[],[],2,26,27,[],"['pfe', 'myl']",https://twitter.com/SquawkCNBC/status/1155793014511558656,False,,1,https://pbs.twimg.com/media/EAoznirW4AAOd-k.jpg,,,,,,,[],,,,
1155792819119955969,1155792819119955969,2019-07-29 16:20:56 IST,2019-07-29,16:20:56,+0530,59393368,livesquawk,LiveSquawk,,Pfizer 2Q Earnings:  $PFE -Rev: $13.3B (est $13.42B) -Adj EPS: 80C (est 75C) -Sees FY Rev: $50.5-$52.5B (prev saw $52-$54B) -Sees FY Adj EPS: $2.76-$2.86 (prev saw $2.83‚Äì $2.93),ht,[],[],[],0,8,9,[],['pfe'],https://twitter.com/LiveSquawk/status/1155792819119955969,False,,0,,,,,,,,[],,,,
1155792147741904896,1155792147741904896,2019-07-29 16:18:16 IST,2019-07-29,16:18:16,+0530,3426014292,semodough,dough,,"$PFE $MYL official merger release  Pfizer Inc. - Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World‚Äôs Need for Medicine  https://t.co/UtAoQrDUpx",en,[],['https://investors.pfizer.com/investor-news/press-release-details/2019/Mylan-and-Upjohn-a-Division-of-Pfizer-to-Combine-Creating-a-New-Champion-for-Global-Health-Uniquely-Positioned-to-Fulfill-the-Worlds-Need-for-Medicine/default.aspx'],[],0,3,5,[],"['pfe', 'myl']",https://twitter.com/semodough/status/1155792147741904896,False,,0,,,,,,,,[],,,,
1155483296891121664,1155483296891121664,2019-07-28 19:51:00 IST,2019-07-28,19:51:00,+0530,112872946,biostocks,Bio Stocks‚Ñ¢,,$PFE &amp; $MYL reportedly near merger deal for off-patent drugs.  Pfizer‚Äôs Michael Goettler would be CEO of the new business   https://t.co/Qb7FOcQoyx #pharma,en,[],['https://www.bloomberg.com/news/articles/2019-07-27/pfizer-nears-deal-to-combine-off-patent-drug-unit-with-mylan-dj'],[],1,3,8,['pharma'],"['pfe', 'myl']",https://twitter.com/BioStocks/status/1155483296891121664,False,,0,,,,,,,,[],,,,
1155374890695966720,1155374890695966720,2019-07-28 12:40:14 IST,2019-07-28,12:40:14,+0530,4392877043,zfxtrading,Miad Kasravi,,Earnings in coming week:  Merck (MRK) Pfizer (PFE) Procter &amp; Gamble (PG) Apple (AAPL) General Electric (GE) Qualcomm (QCOM) General Motors (GM) Verizon (VZ) Exxon Mobil (XOM),en,[],[],[],0,5,22,[],[],https://twitter.com/ZFXtrading/status/1155374890695966720,False,,0,,,,,,,,[],,,,
1155236567851634689,1155236567851634689,2019-07-28 03:30:35 IST,2019-07-28,03:30:35,+0530,632341632,andybiotech,Andy Biotech,,Looks like Merger Monday is back   $EXAS $GHDX Exact Sciences Is Said to Be in Talks to Buy Genomic Health    https://t.co/UffAuo00BU  $PFE $MYL Pfizer Nears Deal to Combine Off-Patent Drug Business With Mylan  https://t.co/hDz9KblaCA,en,[],"['https://www.bloomberg.com/news/articles/2019-07-27/exact-sciences-is-said-to-be-in-talks-to-buy-genomic-health', 'https://www.wsj.com/articles/pfizer-nears-deal-to-combine-off-patent-drug-business-with-mylan-11564228743?mod=hp_lead_pos1']",[],8,58,114,[],"['exas', 'ghdx', 'pfe', 'myl']",https://twitter.com/AndyBiotech/status/1155236567851634689,False,,0,,,,,,,,[],,,,
1155087151333289984,1155087151333289984,2019-07-27 17:36:52 IST,2019-07-27,17:36:52,+0530,3203314919,cararlombardo,Cara Lombardo,,.@WSJ scoop: Pfizer is nearing a deal to combine its off-patent drug business with Mylan and create a giant generics company housing both Viagra and EpiPens. W/ ‚Å¶@jonathanrockoff‚Å© $PFE $MYL  https://t.co/yRKyJ0TRtY,en,"[{'screen_name': 'wsj', 'name': 'the wall street journal', 'id': '3108351'}, {'screen_name': 'jonathanrockoff', 'name': 'jonathan rockoff', 'id': '18021517'}]",['https://www.wsj.com/articles/pfizer-nears-deal-to-combine-off-patent-drug-business-with-mylan-11564228743'],[],2,19,27,[],"['pfe', 'myl']",https://twitter.com/CaraRLombardo/status/1155087151333289984,False,,0,,,,,,,,[],,,,
1155043443258941440,1155043443258941440,2019-07-27 14:43:11 IST,2019-07-27,14:43:11,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,Are you @SangamoTx building #genetherapy manufacturing capabilities or Cell Therapy man. capabilities? Guggenheim quoted the latter. Does this mean full blown GT partnership with @pfizer and focus on CAR Treg infinite pipeline? $SGMO $PFE @BoisselStephane   https://t.co/4MQDdQ2U7O,en,"[{'screen_name': 'sangamotx', 'name': 'sangamo therapeutics', 'id': '809083633671643136'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'boisselstephane', 'name': 'stephane boissel', 'id': '2580053524'}]",['https://www.investorvillage.com/smbd.asp?mb=1933&mn=131014&pt=msg&mid=19630457'],[],1,2,8,['genetherapy'],"['sgmo', 'pfe']",https://twitter.com/Biotech2050/status/1155043443258941440,False,,0,,,,,,,,[],,,,
1148612380361973760,1148612380361973760,2019-07-09 20:48:26 IST,2019-07-09,20:48:26,+0530,223589965,gantosj,Joe,,"MS finally digested $PFE data &amp; compare it well to $SRPT's Magnitude of efficacy difference is at least 3x, wider than the headlines suggest: We used a proprietary approach to analyze Pfizer‚Äôs efficacy data and believe micro-dystrophin expression is actually closer to ~15%    1/2",en,[],[],[],2,2,22,[],"['pfe', 'srpt']",https://twitter.com/GantosJ/status/1148612380361973760,False,,0,,,,,,,,[],,,,
1148155985527267328,1148155985527267328,2019-07-08 14:34:53 IST,2019-07-08,14:34:53,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,MorganStanley: $SGMO $PFE Rival Drug in Hemophilia A:  Sangamo/Pfizer‚Äôs Gene Therapy Shows Solid Ph1/2 Results  Potential rival to $RHHBY ROCHE / Chugai‚Äôs hemophilia A drug #Hemlibra in the medium/long-term #ISTH2019,en,[],[],[],0,8,8,"['hemlibra', 'isth2019']","['sgmo', 'pfe', 'rhhby']",https://twitter.com/_B_I_O_T_E_C_H_/status/1148155985527267328,False,,0,,,,,,,,[],,,,
1147746836800839680,1147746836800839680,2019-07-07 11:29:04 IST,2019-07-07,11:29:04,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,Comparison of US FDA Breakthrough vs RMAT designation  ( $PFE $SGMO announced at #ISTH2019 that they received first ever RMAT designation in #hemophilia #genetherapy which could facilitate accelerated approval) cc @pfizer @SangamoTx @endpts  https://t.co/gXBEoW2yuf,en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'sangamotx', 'name': 'sangamo therapeutics', 'id': '809083633671643136'}, {'screen_name': 'endpts', 'name': 'endpoints news', 'id': '3460109487'}]",['https://pharmaintelligence.informa.com/resources/product-content/us-fdas-breakthrough-and-rmat-designations-a-quick-guide'],[],0,7,10,"['isth2019', 'hemophilia', 'genetherapy']","['pfe', 'sgmo']",https://twitter.com/Biotech2050/status/1147746836800839680,False,,0,,,,,,,,[],,,,
1147432549851062272,1147432549851062272,2019-07-06 14:40:12 IST,2019-07-06,14:40:12,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,The first ever #hemophilia A #genetherapy RMAT designation given to $SGMO SB-525 at #ISTH2019 validates @SangamoTx' s platform and can be replicated in multiple #RareDisease indications. What do you think @pfizer $PFE next move be? cc @JohnCendpts @matthewherper @ScottGottliebMD,en,"[{'screen_name': 'sangamotx', 'name': 'sangamo therapeutics', 'id': '809083633671643136'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'johncendpts', 'name': 'john carroll', 'id': '102754598'}, {'screen_name': 'matthewherper', 'name': 'matthew herper', 'id': '44438256'}, {'screen_name': 'scottgottliebmd', 'name': 'scott gottlieb, md', 'id': '40156330'}]",[],[],0,6,12,"['hemophilia', 'genetherapy', 'isth2019', 'raredisease']","['sgmo', 'pfe']",https://twitter.com/Biotech2050/status/1147432549851062272,False,,0,,,,,,,,[],,,,
1147384867291664385,1147363931155042304,2019-07-06 11:30:44 IST,2019-07-06,11:30:44,+0530,718735465923416064,jlpcoins,jlpcoins@nobody,,@Biotech2050 @SangamoTx @pfizer @BoisselStephane @AdrianWoolfson $SGMO data is excellent and superior to peers $BMRN $ONCE.  RMAT helps SGMO. It‚Äôs a big plus. Upgrades coming Monday. $SNY $GILD $PFE should all have inc interest in buying SGMO. Shorts are in trouble next week and beyond.,en,[],[],[],0,5,10,[],"['sgmo', 'bmrn', 'once', 'sny', 'gild', 'pfe']",https://twitter.com/jlpcoins/status/1147384867291664385,False,,0,,,,,,,,"[{'screen_name': 'Biotech2050', 'name': 'Biotech2050', 'id': '2494896473'}, {'screen_name': 'SangamoTx', 'name': 'Sangamo Therapeutics', 'id': '809083633671643136'}, {'screen_name': 'pfizer', 'name': 'Pfizer Inc.', 'id': '56488059'}, {'screen_name': 'BoisselStephane', 'name': 'Stephane Boissel', 'id': '2580053524'}, {'screen_name': 'AdrianWoolfson', 'name': 'AdrianWoolfson', 'id': '393682087'}]",,,,
1147370041270263809,1147370041270263809,2019-07-06 10:31:49 IST,2019-07-06,10:31:49,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"Experimental gene therapy for hemophilia, developed by $PFE Pfizer and $SGMO Sangamo, shows promise #ISTH2019   https://t.co/TdgdlBTYZN",en,[],['https://www.statnews.com/2019/07/05/experimental-gene-therapy-for-hemophilia-developed-by-pfizer-and-sangamo-shows-early-promise/'],[],0,8,16,['isth2019'],"['pfe', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/1147370041270263809,False,,0,,,,,,,,[],,,,
1147044351681470464,1147044351681470464,2019-07-05 12:57:39 IST,2019-07-05,12:57:39,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,The Final Countdown  #hemophilia #genetherapy at #ISTH2019  $BMRN $SGMO $ONCE $PFE $SNY @TakedaPharma @Roche @Pfizer @SangamoTx @BoisselStephane @spark_tx   https://t.co/W3UO5uv6Cz,en,"[{'screen_name': 'takedapharma', 'name': 'takeda', 'id': '46654897'}, {'screen_name': 'roche', 'name': 'roche', 'id': '20815041'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'sangamotx', 'name': 'sangamo therapeutics', 'id': '809083633671643136'}, {'screen_name': 'boisselstephane', 'name': 'stephane boissel', 'id': '2580053524'}, {'screen_name': 'spark_tx', 'name': 'spark therapeutics', 'id': '1921290120'}]",['https://youtu.be/9jK-NcRmVcw'],[],1,3,7,"['hemophilia', 'genetherapy', 'isth2019']","['bmrn', 'sgmo', 'once', 'pfe', 'sny']",https://twitter.com/Biotech2050/status/1147044351681470464,False,,0,,,,,,,,[],,,,
1147011138896433152,1147011138896433152,2019-07-05 10:45:40 IST,2019-07-05,10:45:40,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,In 22 hours at #ISTH2019 $PFE $SGMO updated data from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy in patients with severe hemophilia A. SB-525 is being developed as part of a global collaboration between @SangamoTx and @pfizer.  https://t.co/dsarwytpyu,en,"[{'screen_name': 'sangamotx', 'name': 'sangamo therapeutics', 'id': '809083633671643136'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}]",['https://investor.sangamo.com/news-releases/news-release-details/sangamo-announces-upcoming-presentation-investigational-sb-525'],[],0,9,7,['isth2019'],"['pfe', 'sgmo']",https://twitter.com/Biotech2050/status/1147011138896433152,False,,0,,,,,,,,[],,,,
1146763251511910400,1145894107711193089,2019-07-04 18:20:39 IST,2019-07-04,18:20:39,+0530,1336746709,greyzone513,Grey Zone,,@beauregard2 @bad_trades @StunningFeline @ericgcomo @adamfeuerstein @matthewherper Actually I think n= 4 + 12 = 16 is more accurate. 12 placebo/12 treated in $SRPT confirmatory. Still far greater than 4 and as DI clearly stated without significant AE‚Äôs to date vs 1/3 of those treated for Pfizer. Additionally $PFE had lack luster uD production = effectively done,en,[],[],[],1,1,13,[],"['srpt', 'pfe']",https://twitter.com/greyzone513/status/1146763251511910400,False,,0,,,,,,,,"[{'screen_name': 'beauregard2', 'name': 'beauregard', 'id': '57921721'}, {'screen_name': 'Bad_Trades', 'name': 'Bad Trades', 'id': '1361014490330972160'}, {'screen_name': 'StunningFeline', 'name': 'Joel', 'id': '153911771'}, {'screen_name': 'ericgcomo', 'name': 'Eric Gilbert', 'id': '757676190'}, {'screen_name': 'adamfeuerstein', 'name': 'Adam Feuerstein', 'id': '102094857'}, {'screen_name': 'matthewherper', 'name': 'Matthew Herper', 'id': '44438256'}]",,,,
1146672179628498946,1146663607591153664,2019-07-04 12:18:46 IST,2019-07-04,12:18:46,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,@TomReiser @MCEC Thomas make sure that there is video coverage of the update which @pfizer and @SangamoTx will jointly give for their #hemophilia trial (and tweet this video pls).  #ISTH2019 might be the venue where #genetherapy is recognised as leapfrogging conventional medicine. $SGMO $PFE,en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'sangamotx', 'name': 'sangamo therapeutics', 'id': '809083633671643136'}]",[],[],0,4,11,"['hemophilia', 'isth2019', 'genetherapy']","['sgmo', 'pfe']",https://twitter.com/Biotech2050/status/1146672179628498946,False,,0,,,,,,,,"[{'screen_name': 'TomReiser', 'name': 'Thomas Reiser', 'id': '32816770'}, {'screen_name': 'MCEC', 'name': 'MCEC', 'id': '19223556'}]",,,,
1146445416352886784,1146445028111392768,2019-07-03 21:17:41 IST,2019-07-03,21:17:41,+0530,120949245,phatoftheland10,JO-BU,,@ReformedBroker @CNBCClosingBell The run in Sarepta and how its not getting the respect it deserves after Pfizer dropped the ball with their Gene Therapy. $srpt $PFE #GeneTherapy,en,[],[],[],0,0,4,['genetherapy'],"['srpt', 'pfe']",https://twitter.com/phatoftheland10/status/1146445416352886784,False,,0,,,,,,,,"[{'screen_name': 'ReformedBroker', 'name': 'Downtown Josh Brown', 'id': '22522178'}, {'screen_name': 'CNBCClosingBell', 'name': ""CNBC's Closing Bell"", 'id': '21778391'}]",,,,
1146061141392515074,1146061141392515074,2019-07-02 19:50:43 IST,2019-07-02,19:50:43,+0530,13171622,pharmalot,pharmalot,,Elizabeth Warren blasts former FDA commish Scott Gottlieb for joining the Pfizer board..  https://t.co/9005Ut4fKU #pharma #ElizabethWarren #revolvingdoor $PFE,en,[],['https://www.statnews.com/2019/07/02/warren-blasts-gottlieb-pfizer-board/'],[],1,4,6,"['pharma', 'elizabethwarren', 'revolvingdoor']",['pfe'],https://twitter.com/pharmalot/status/1146061141392515074,False,,0,,,,,,,,[],,,,
1145887821284151297,1145887821284151297,2019-07-02 08:22:00 IST,2019-07-02,08:22:00,+0530,3460109487,endpts,Endpoints News,,Pfizer‚Äôs gamble on a new lease on life for aging sildenafil franchise fizzles in PhIII  https://t.co/HCQYDeP8cg $PFE,en,[],['https://endpts.com/pfizers-gamble-on-a-new-lease-on-life-for-aging-sildenafil-franchise-fizzles-in-phiii/'],[],0,0,5,[],['pfe'],https://twitter.com/endpts/status/1145887821284151297,False,,0,,,,,,,,[],,,,
1145719587662651394,1145719587662651394,2019-07-01 21:13:30 IST,2019-07-01,21:13:30,+0530,223589965,gantosj,Joe,,DMD Data by Giant Pharma Pfizer Kept Sarepta In the Driver Seat with Superior Drug $SRPT $PFE    https://t.co/EBpP3CEiPi  https://t.co/iKOPtKgy29,en,[],['https://www.chimeraresearchgroup.com/2019/07/dmd-data-by-giant-pharma-pfizer-kept-sarepta-in-the-driver-seat-with-superior-drug/'],['https://pbs.twimg.com/media/D-Zp10aWkAIq9vu.jpg'],0,4,17,[],"['srpt', 'pfe']",https://twitter.com/GantosJ/status/1145719587662651394,False,,1,https://pbs.twimg.com/media/D-Zp10aWkAIq9vu.jpg,,,,,,,[],,,,
1145712503009230848,1145712503009230848,2019-07-01 20:45:21 IST,2019-07-01,20:45:21,+0530,44438256,matthewherper,Matthew Herper,,"Pfizer, Sarepta, and gene therapy: A race for a better Duchenne treatment  ‚Å¶@adamfeuerstein‚Å© and I talk $pfe and $srpt here. Read a transcript.  https://t.co/slnqCIy2jb",en,"[{'screen_name': 'adamfeuerstein', 'name': 'adam feuerstein', 'id': '102094857'}]",['https://www.statnews.com/2019/07/01/the-race-for-a-better-duchenne-treatment-adam-and-matt-talk-pfizer-sarepta-and-gene-therapy/'],[],4,2,10,[],"['pfe', 'srpt']",https://twitter.com/matthewherper/status/1145712503009230848,False,,0,,,,,,,,[],,,,
1145712313724547077,1145712313724547077,2019-07-01 20:44:36 IST,2019-07-01,20:44:36,+0530,44438256,matthewherper,Matthew Herper,,"Pfizer, Sarepta, and gene therapy: A race for a better Duchenne treatment  Adam and I talk $srpt and $pfe here.  https://t.co/slnqCIy2jb",en,[],['https://www.statnews.com/2019/07/01/the-race-for-a-better-duchenne-treatment-adam-and-matt-talk-pfizer-sarepta-and-gene-therapy/'],[],0,3,8,[],"['srpt', 'pfe']",https://twitter.com/matthewherper/status/1145712313724547077,False,,0,,,,,,,,[],,,,
1145707168529825794,1145707168529825794,2019-07-01 20:24:09 IST,2019-07-01,20:24:09,+0530,290158392,chimeraresearch,ChimeraResearchGroup,,DMD Data by Giant Pharma Pfizer Kept Sarepta In the Driver Seat with Superior Drug $PFE $sldb $SRPT  https://t.co/25y5UncJgi,en,[],['https://www.chimeraresearchgroup.com/2019/07/dmd-data-by-giant-pharma-pfizer-kept-sarepta-in-the-driver-seat-with-superior-drug/'],[],1,3,9,[],"['pfe', 'sldb', 'srpt']",https://twitter.com/ChimeraResearch/status/1145707168529825794,False,,0,,,,,,,,[],,,,
1145680088941420544,1145680088941420544,2019-07-01 18:36:33 IST,2019-07-01,18:36:33,+0530,1631501168,jfruehauf,Johannes Fruehauf,,Read how @Pfizer Grants Golden Tickets to Biotech Startups @LabCentral to accelerate #innovation. Founders - apply before August 23 !  https://t.co/1DVhPxrMAD via @MedTechBoston @pfizer $PFE #startups,en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'labcentral', 'name': 'labcentral', 'id': '213429445'}, {'screen_name': 'medtechboston', 'name': 'medtech boston', 'id': '1941314394'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}]",['https://wp.me/p6JlU2-5Y0'],[],0,8,6,"['innovation', 'startups']",['pfe'],https://twitter.com/JFruehauf/status/1145680088941420544,False,,0,,,,,,,,[],,,,
1144792737704792064,1144792737704792064,2019-06-29 07:50:32 IST,2019-06-29,07:50:32,+0530,54671491,welshinator,Trent Welsh,,I would not be surprised if Sarepta $SRPT made a run at $200 a share by year end with a slow grind higher with jumps. Pfizer $PFE just doesn‚Äôt have the safety profile that Sarepta has and is over a year ahead of Pfizer in gene therapy. Look for reratings and upgrades next week.,en,[],[],[],3,3,19,[],"['srpt', 'pfe']",https://twitter.com/welshinator/status/1144792737704792064,False,,0,,,,,,,,[],,,,
1144713357477535745,1144713357477535745,2019-06-29 02:35:06 IST,2019-06-29,02:35:06,+0530,3300833041,ibd_rbritt,Russ Britt,,Sarepta Therapeutics $SRPT shares rocketed Friday after Pfizer $PFE said its gene therapy test is on pause following serious side effects in two boys with Duchenne muscular dystrophy. .... IBD's Allison Gatlin @IBD_AGatlin explains. ....  https://t.co/KpPfsT1fAJ,en,"[{'screen_name': 'ibd_agatlin', 'name': 'allison gatlin', 'id': '3300865039'}]",['http://ow.ly/bm5Z50uPuVa'],[],0,3,8,[],"['srpt', 'pfe']",https://twitter.com/IBD_RBritt/status/1144713357477535745,False,,0,,,,,,,,[],,,,
1144691323045330945,1144691323045330945,2019-06-29 01:07:33 IST,2019-06-29,01:07:33,+0530,427877977,portefeuillefun,Volker Schulz,,"$SRPT $PFE. 'Almost impossible' for #Pfizer to compete with #Sarepta, says Piper Jaffray  https://t.co/9D3d15ynOm.  https://t.co/IRTlTriSEZ",en,[],['https://thefly.com/landingPageNews.php?id=2928031'],['https://pbs.twimg.com/media/D-LCrquW4AAZT3b.png'],0,0,12,"['pfizer', 'sarepta']","['srpt', 'pfe']",https://twitter.com/portefeuillefun/status/1144691323045330945,False,,1,https://pbs.twimg.com/media/D-LCrquW4AAZT3b.png,,,,,,,[],,,,
1144679879750742016,1144679879750742016,2019-06-29 00:22:05 IST,2019-06-29,00:22:05,+0530,166597717,theflynews,The Fly,,"'Almost impossible' for Pfizer to compete with Sarepta, says Piper Jaffray $SRPT $PFE $SLDB  https://t.co/P3GJ9PBQoW",en,[],['http://dlvr.it/R7Sjck'],[],0,2,9,[],"['srpt', 'pfe', 'sldb']",https://twitter.com/theflynews/status/1144679879750742016,False,,0,,,,,,,,[],,,,
1144628364541452289,1144066568256512000,2019-06-28 20:57:22 IST,2019-06-28,20:57:22,+0530,950942636818432006,syinvesting,SY Investing,,"Update from @BrianSkorney after $PFE &amp; $SRPT #DMD updates:  ""Is it over for Pfizer? Probably not, but we think it should be.""",en,"[{'screen_name': 'brianskorney', 'name': 'brian skorney', 'id': '285598594'}]",[],[],0,3,17,['dmd'],"['pfe', 'srpt']",https://twitter.com/syinvesting/status/1144628364541452289,False,,0,,,,,,,,[],,,,
1144624054881660935,1144624054881660935,2019-06-28 20:40:15 IST,2019-06-28,20:40:15,+0530,47678782,megtirrell,Meg Tirrell,,"Wall Street reax coming in on $PFE DMD update.   Baird's @BrianSkorney: ""Is it over for Pfizer? Probably not, but we think it should be.""  $SRPT",en,"[{'screen_name': 'brianskorney', 'name': 'brian skorney', 'id': '285598594'}]",[],[],0,5,35,[],"['pfe', 'srpt']",https://twitter.com/megtirrell/status/1144624054881660935,False,,0,,,,,,,,[],,,,
1144616536608403457,1144616536608403457,2019-06-28 20:10:22 IST,2019-06-28,20:10:22,+0530,950942636818432006,syinvesting,SY Investing,,"$SRPT Doug Ingram at #PPMD:  ""There is no one on this stage that is currently a competitor of Sarepta. I don't consider my colleagues at Pfizer as a competitor. We only have one competitor on this mission, and that's #DMD.""  $PFE $SLDB",en,[],[],[],0,1,17,"['ppmd', 'dmd']","['srpt', 'pfe', 'sldb']",https://twitter.com/syinvesting/status/1144616536608403457,False,,0,,,,,,,,[],,,,
1144610224122343424,1144609855375839232,2019-06-28 19:45:17 IST,2019-06-28,19:45:17,+0530,19717430,zbiotech,zach,,"*PFIZER PLANS TO RESUME TRIAL, START PHASE 3 BY JUNE 2020  $PFE $SRPT  https://t.co/Zyi4knlEsE",en,[],[],['https://pbs.twimg.com/media/D-J47mzWsAEBBBO.jpg'],0,5,6,[],"['pfe', 'srpt']",https://twitter.com/zbiotech/status/1144610224122343424,False,,1,https://pbs.twimg.com/media/D-J47mzWsAEBBBO.jpg,,,,,,,[],,,,
1144586717141315585,1144586717141315585,2019-06-28 18:11:53 IST,2019-06-28,18:11:53,+0530,3426014292,semodough,dough,,"JP At 9:50am ET: Watch the $PFE DMD presentation at PPMD (link here), with an expected PR after the presentation. Keep in mind the quick presentation line up: Solid @ 9:30am, Pfizer @9:50am, $SRPT  @10:10am.  And I add $FGEN 1200 eastern also",en,"[{'screen_name': '10', 'name': 'k', 'id': '7888952'}]",[],[],1,3,14,[],"['pfe', 'srpt', 'fgen']",https://twitter.com/semodough/status/1144586717141315585,False,,0,,,,,,,,[],,,,
1144578874904178688,1144578874904178688,2019-06-28 17:40:43 IST,2019-06-28,17:40:43,+0530,223589965,gantosj,Joe,,"PPMD live webcast  9:30  $SLDB Solid Genevieve A. Laforet, MD, PhD 9:50 $PFE Pfizer Michael Binks, MD 10:10 $SRPT Sarepta Doug Ingram 10:30 Q&amp;A   https://t.co/42mkxpRa1I",en,[],['https://www.youtube.com/watch?v=U_Xo5C-Yn0M&feature=youtu.be'],[],3,12,23,[],"['sldb', 'pfe', 'srpt']",https://twitter.com/GantosJ/status/1144578874904178688,False,,0,,,,,,,,[],,,,
1144373465941716992,1144373465941716992,2019-06-28 04:04:30 IST,2019-06-28,04:04:30,+0530,13171622,pharmalot,pharmalot,,"Scott Gottlieb walks through the revolving door to the Pfizer board.. 'He's returning to the ecosystem where he's most comfortable,' says a wag..  https://t.co/r6tvoZhEv2 #pharma #FDA $PFE #Trump #drugprices",en,[],['https://www.statnews.com/pharmalot/2019/06/27/scott-gottlieb-pfizer-board-fda/'],[],2,27,27,"['pharma', 'fda', 'trump', 'drugprices']",['pfe'],https://twitter.com/pharmalot/status/1144373465941716992,False,,0,,,,,,,,[],,,,
1144345386208960512,1144343404186361856,2019-06-28 02:12:55 IST,2019-06-28,02:12:55,+0530,331679274,chuckhabz,Chuck H,,"@ScottGottliebMD @pfizer Congratulations. Hopefully you can help $PFE find cureS for ALS.  Please, your WPT neighbor needs cureS.   #EndALS #IAmALS",en,[],[],[],2,1,4,"['endals', 'iamals']",['pfe'],https://twitter.com/ChuckHabz/status/1144345386208960512,False,,0,,,,,,,,"[{'screen_name': 'ScottGottliebMD', 'name': 'Scott Gottlieb, MD', 'id': '40156330'}, {'screen_name': 'pfizer', 'name': 'Pfizer Inc.', 'id': '56488059'}]",,,,
1144340815130648577,1144340815130648577,2019-06-28 01:54:45 IST,2019-06-28,01:54:45,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,I had sent @SGottliebFDA a tweet to join Sangamo's board and he went one step further up! $SGMO' s buyout by $PFE is now inevitable. As a minimum the copy and paste (replication) of multiple #genetherapy partnerships is now a done deal Congrats @pfizer @SangamoTx,en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'sangamotx', 'name': 'sangamo therapeutics', 'id': '809083633671643136'}]",[],[],1,7,18,['genetherapy'],"['sgmo', 'pfe']",https://twitter.com/Biotech2050/status/1144340815130648577,False,https://twitter.com/zbiotech/status/1144338938997485568,0,,,,,,,,[],,,,
1144338938997485568,1144338938997485568,2019-06-28 01:47:18 IST,2019-06-28,01:47:18,+0530,19717430,zbiotech,zach,,Scott Gottlieb Elected to Pfizer‚Äôs Board of Directors  $PFE,en,[],[],[],19,36,79,[],['pfe'],https://twitter.com/zbiotech/status/1144338938997485568,False,,0,,,,,,,,[],,,,
1144227652821291008,1144227652821291008,2019-06-27 18:25:05 IST,2019-06-27,18:25:05,+0530,25998862,drugchannels,Adam J. Fein,,"Latest plan #formulary analysis from Ronny Gal @AB_insights: #Remicade (@JanssenUS $JNJ) remains ""heavily preferred"" over #biosimilars #Inflectra (@pfizer $PFE) and #Renflexis (@Merck $MRK), both of which are step edited. (Sorry, full report not available for posting)  https://t.co/7nZc0IQ1MR",en,"[{'screen_name': 'ab_insights', 'name': 'alliancebernstein (ab)', 'id': '360041082'}, {'screen_name': 'janssenus', 'name': 'janssenus', 'id': '256182836'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'merck', 'name': 'merck', 'id': '35961145'}]",[],['https://pbs.twimg.com/media/D-Ec_F1XoAUAb6A.jpg'],0,1,11,"['formulary', 'remicade', 'biosimilars', 'inflectra', 'renflexis']","['jnj', 'pfe', 'mrk']",https://twitter.com/DrugChannels/status/1144227652821291008,False,,1,https://pbs.twimg.com/media/D-Ec_F1XoAUAb6A.jpg,,,,,,,[],,,,
1144066568256512000,1144066568256512000,2019-06-27 07:45:00 IST,2019-06-27,07:45:00,+0530,950942636818432006,syinvesting,SY Investing,,"Brian Skorney's (Baird) take on $PFE and $SRPT in #DMD ahead of Friday's showdown:  ""We remain positively inclined into this dataset as Sarepta has set the bar so high with its results last year, we think Pfizer is likely to fall short on safety, efficacy or both.""",en,[],[],[],1,5,33,['dmd'],"['pfe', 'srpt']",https://twitter.com/syinvesting/status/1144066568256512000,False,,0,,,,,,,,[],,,,
1143939978772267009,1143939978772267009,2019-06-26 23:21:58 IST,2019-06-26,23:21:58,+0530,1631501168,jfruehauf,Johannes Fruehauf,,Calling entrepreneurs and startups in Boston - Our sponsors @pfizer just opened the application period for their 2019/20 @labcentral golden tickets. This could win you a year worth of free rent at LabCentral alongside with a coveted partnership with $PFE!   https://t.co/l3ufT3is1D,en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'labcentral', 'name': 'labcentral', 'id': '213429445'}]",['https://www.pfizer.com/science/research-development/centers/ma_cambridge/golden_ticket'],[],0,8,16,[],['pfe'],https://twitter.com/JFruehauf/status/1143939978772267009,False,,0,,,,,,,,[],,,,
1143320142798938112,1141050444438888449,2019-06-25 06:18:58 IST,2019-06-25,06:18:58,+0530,950942636818432006,syinvesting,SY Investing,,"Pre-look from Evercore ISI ahead of Pfizer #DMD data release on 6/28  - $SRPT, $PFE &amp; $SLDB ¬µDyst. constructs encode for different proteins - Asymmetric upside for SRPT from efficacy and safety profile expectations - Asymmetric downside for SRPT from faster timeline / mfg updates  https://t.co/Yu0FM2NVsm",en,[],[],"['https://pbs.twimg.com/media/D93cy1MUcAERJ-1.jpg', 'https://pbs.twimg.com/media/D93czvWUwAAksWU.jpg', 'https://pbs.twimg.com/media/D93c0ipU8AAA5H1.jpg', 'https://pbs.twimg.com/media/D93c1TkU8AAgjWW.jpg']",3,5,8,['dmd'],"['srpt', 'pfe', 'sldb']",https://twitter.com/syinvesting/status/1143320142798938112,False,,1,https://pbs.twimg.com/media/D93cy1MUcAERJ-1.jpg,,,,,,,[],,,,
1143213764864618498,1143213764864618498,2019-06-24 23:16:16 IST,2019-06-24,23:16:16,+0530,33599813,love2scuba_f,FrogFish,,"Marai says ""Creatine kinase levels might be the strongest indicator Pfizer's gene therapy works, Marai said. Muscle cells need this enzyme to function. But the PFE is unlikely to discuss that measure"", so much for that presentation. $srpt",en,[],[],[],0,0,9,[],['srpt'],https://twitter.com/love2scuba_f/status/1143213764864618498,False,,0,,,,,,,,[],,,,
1143158378178461696,1143158378178461696,2019-06-24 19:36:10 IST,2019-06-24,19:36:10,+0530,1336746709,greyzone513,Grey Zone,,"$SRPT $PFE  At Pfizer‚Äôs ‚Äúhigh‚Äù dose, a 40kg patient, would receive about 2,000 trillion additional capsids compared to the dose Sarepta is using. That's ‚Äú3,200 Milky Way galaxies‚Äù. All available to cross BB barrier too. What could possibly go wrong?",en,[],[],[],2,0,20,[],"['srpt', 'pfe']",https://twitter.com/greyzone513/status/1143158378178461696,False,,0,,,,,,,,[],,,,
1142061706786553856,1142061706786553856,2019-06-21 18:58:24 IST,2019-06-21,18:58:24,+0530,54671491,welshinator,Trent Welsh,,Pfizer $PFE data at three times the viral load of Sarepta‚Äôs $SRPT. Good luck. Golo is almost a certainty with casi coming early 2020. New Gene therapy data will push it to new highs if it continues to impress. Exciting 2H/19 for sure after boring last few months.,en,[],[],[],0,0,17,[],"['pfe', 'srpt']",https://twitter.com/welshinator/status/1142061706786553856,False,https://twitter.com/semodough/status/1142038767273938945,0,,,,,,,,[],,,,
1141191122653536257,1141191122653536257,2019-06-19 09:19:00 IST,2019-06-19,09:19:00,+0530,3460109487,endpts,Endpoints News,,"Right back at you, Pfizer: BeiGene and a Pfizer spinout launch a newco to develop a MEK/BRAF inhibitor that could rival $11.4B combo  https://t.co/x9uio0XOq5 $PFE",en,[],['https://endpts.com/right-back-at-you-pfizer-beigene-and-a-pfizer-spinout-launch-a-newco-to-develop-a-mek-braf-inhibitor-that-could-rival-11-4b-combo/'],[],0,2,7,[],['pfe'],https://twitter.com/endpts/status/1141191122653536257,False,,0,,,,,,,,[],,,,
1140673448211025921,1140673448211025921,2019-06-17 23:01:57 IST,2019-06-17,23:01:57,+0530,1280320154,byamybrown,Amy Brown,,"Rich recognition finally arrives for Array. Our take on the $11bn Pfizer buyout, including a look at upcoming trial readouts and potential royalty streams. via @vantageanalysis   https://t.co/FCAeA3egGr $PFE $ARRY  https://t.co/8GSAqPMCW5",en,"[{'screen_name': 'vantageanalysis', 'name': 'evaluate vantage', 'id': '3033767986'}]",['https://www.evaluate.com/vantage/articles/news/deals/rich-recognition-finally-arrives-array'],['https://pbs.twimg.com/media/D9R8O4cXYAEFw2V.png'],1,11,16,[],"['pfe', 'arry']",https://twitter.com/ByAmyBrown/status/1140673448211025921,False,,1,https://pbs.twimg.com/media/D9R8O4cXYAEFw2V.png,,,,,,,[],,,,
1140599974796955648,1140599974796955648,2019-06-17 18:09:59 IST,2019-06-17,18:09:59,+0530,102094857,adamfeuerstein,Adam Feuerstein,,Pfizer spends $11.4 billion to buy Array BioPharma for its cancer drug chemistry  https://t.co/Yv5kXsfOOQ via @matthewherper $PFE $ARRY,en,"[{'screen_name': 'matthewherper', 'name': 'matthew herper', 'id': '44438256'}]",['https://www.statnews.com/2019/06/17/pfizer-buys-array-biopharma-for-its-cancer-drug-chemistry/'],[],2,7,9,[],"['pfe', 'arry']",https://twitter.com/adamfeuerstein/status/1140599974796955648,False,,0,,,,,,,,[],,,,
1140599722866094081,1140599722866094081,2019-06-17 18:08:59 IST,2019-06-17,18:08:59,+0530,44438256,matthewherper,Matthew Herper,,Pfizer spends $11.4 billion to buy Array BioPharma for its cancer drug chemistry $ARRY $PFE  https://t.co/5DoOA0haRF,en,[],['https://www.statnews.com/2019/06/17/pfizer-buys-array-biopharma-for-its-cancer-drug-chemistry/'],[],1,7,15,[],"['arry', 'pfe']",https://twitter.com/matthewherper/status/1140599722866094081,False,,0,,,,,,,,[],,,,
1140572312456114176,1140572312456114176,2019-06-17 16:20:04 IST,2019-06-17,16:20:04,+0530,801116888,cfromhertz,Christian Fromhertz,,Pfizer Agrees to Buy Array for $48/Share in Cash $PFE $ARRY,en,[],[],[],1,1,8,[],"['pfe', 'arry']",https://twitter.com/cfromhertz/status/1140572312456114176,False,,0,,,,,,,,[],,,,
1140571221441970177,1140571221441970177,2019-06-17 16:15:44 IST,2019-06-17,16:15:44,+0530,112872946,biostocks,Bio Stocks‚Ñ¢,,$PFE Pfizer To Acquire Array BioPharma $ARRY,de,[],[],[],4,35,53,[],"['pfe', 'arry']",https://twitter.com/BioStocks/status/1140571221441970177,False,,0,,,,,,,,[],,,,
1138858067066593287,1138858067066593287,2019-06-12 22:48:16 IST,2019-06-12,22:48:16,+0530,2875375685,montecristo_bm,Montecristo,,"$PFE  PFIZER  Vemos como los valores alcistas contin√∫an üìà y, como las acciones que generan se√±ales t√©cnicas fuera de contexto nos genera un buen Timing y, pasan cosas como esta.   Despu√©s de tres d√©cadas, puedo decir que soy un entusiasta de los mercados üòâ.  üëá  https://t.co/uerNrfXZ5X",es,[],[],['https://pbs.twimg.com/media/D84IdaVWkAAJlBb.png'],0,1,12,[],['pfe'],https://twitter.com/Montecristo_BM/status/1138858067066593287,False,,1,https://pbs.twimg.com/media/D84IdaVWkAAJlBb.png,,,,,,,[],,,,
1136581304823275520,1136581304823275520,2019-06-06 16:01:14 IST,2019-06-06,16:01:14,+0530,102754598,johncendpts,John Carroll,,"Based on response, I can pretty much guarantee you that the industry consensus on the @washingtonpost story on Pfizer and Alzheimer's is that it was overblown nonsense.  $PFE  https://t.co/Ep4n61tWrj",en,"[{'screen_name': 'washingtonpost', 'name': 'the washington post', 'id': '2467791'}]",['https://endpts.com/the-washington-post-points-the-finger-at-pfizer-for-staying-mum-about-an-alzheimers-study-but-theres-more-to-the-story-than-that/'],[],4,11,67,[],['pfe'],https://twitter.com/JohnCendpts/status/1136581304823275520,False,,0,,,,,,,,[],,,,
1136274310874746881,1136274310874746881,2019-06-05 19:41:21 IST,2019-06-05,19:41:21,+0530,44438256,matthewherper,Matthew Herper,,When Peter Bach defends Pfizer. Cc: @megtirrell @scotthensley $PFE $AMGN,de,"[{'screen_name': 'megtirrell', 'name': 'meg tirrell', 'id': '47678782'}, {'screen_name': 'scotthensley', 'name': 'scott hensley', 'id': '18208763'}]",[],[],1,6,12,[],"['pfe', 'amgn']",https://twitter.com/matthewherper/status/1136274310874746881,False,https://twitter.com/peterbachmd/status/1136272297139064834,0,,,,,,,,[],,,,
1134069820696272896,1134069820696272896,2019-05-30 17:41:29 IST,2019-05-30,17:41:29,+0530,494544759,yachmod,Ja Hish,,$SRPT Cruising at 21 kns through Baltic Sea to Pfizer‚Äôs Berlin office via Warnemunde in search of $PFE data. Thought I saw some in the bubbles but they vanished quickly.  https://t.co/TuQEB7lXCP,en,[],[],['https://pbs.twimg.com/media/D70GfD4XYAE1h1S.jpg'],2,0,18,[],"['srpt', 'pfe']",https://twitter.com/yachmod/status/1134069820696272896,False,,1,https://pbs.twimg.com/media/D70GfD4XYAE1h1S.jpg,,,,,,,[],,,,
1131561681816117248,1131561681816117248,2019-05-23 19:35:03 IST,2019-05-23,19:35:03,+0530,3426014292,semodough,dough,,JP good overview on $SRPT $PFE DMD data preview-burden remains competition Pfizer) to put up competitive data relative to $SRPT SRP-9001 PPMD could be a less of an event / definitive read-through for SRPT shares unless there is Western Blot and / or immunohistochemistry,en,[],[],[],2,2,25,[],"['srpt', 'pfe', 'srpt']",https://twitter.com/semodough/status/1131561681816117248,False,,0,,,,,,,,[],,,,
1129830568353574913,1129830568353574913,2019-05-19 00:56:13 IST,2019-05-19,00:56:13,+0530,401575573,dividendc2,dividendc2,,MY TOP5 best companies sector - INNOVATIVE HEALTHCARE -  long term:   1: Johnson &amp; Johnson $JNJ  2: Merck &amp; Co Inc $MRK  3: Pfizer Inc $PFE  4: Eli Lilly and Co $LLY   5: AbbVie Inc $ABBV,en,[],[],[],0,1,9,[],"['jnj', 'mrk', 'pfe', 'lly', 'abbv']",https://twitter.com/dividendc2/status/1129830568353574913,False,,0,,,,,,,,[],,,,
1128293408869683200,1128293408869683200,2019-05-14 19:08:06 IST,2019-05-14,19:08:06,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"$SLDB $PFE WB $SRPT DMD Gene Therapy Competitor Continues to Show Immunogenicity Issues, Pfizer Competition (cont)  https://t.co/Ldz9E1DTZV",en,[],['http://tl.gd/n_1sqsuut'],[],0,3,11,[],"['sldb', 'pfe', 'srpt']",https://twitter.com/_B_I_O_T_E_C_H_/status/1128293408869683200,False,,0,,,,,,,,[],,,,
1127716242322862081,1127716242322862081,2019-05-13 04:54:38 IST,2019-05-13,04:54:38,+0530,593813785,donnayoungdc,Donna Young,,"""""Pfizer, acting through its wholly-owned subsidiary and alter ego‚Ä¶Greenstone, entered into agreements with Teva and...other competitors to allocate and divide customers and markets‚Ä¶and to fix and raise prices."" $PFE $TEVA #pharma #generics #drugprices #drugpricing #60Minutes",en,[],[],[],0,8,8,"['pharma', 'generics', 'drugprices', 'drugpricing', '60minutes']","['pfe', 'teva']",https://twitter.com/DonnaYoungDC/status/1127716242322862081,False,https://twitter.com/60Minutes/status/1127715341545680898,0,,,,,,,,[],,,,
1126568246205919232,1126568246205919232,2019-05-10 00:52:55 IST,2019-05-10,00:52:55,+0530,1012298036490506240,biotechobserver,BiotechObserver,,"Doug alluded to this, but the very fact that Pfizer is going to initially disclose data results at a patient outreach conference also speaks to the overall bioturd approach they've taken to their micro, I mean fake-mini, dystrophin program, doesn't it. All marketing. $SRPT $PFE",en,[],[],[],0,1,13,[],"['srpt', 'pfe']",https://twitter.com/BiotechObserver/status/1126568246205919232,False,,0,,,,,,,,[],,,,
1126519678015299584,1126519678015299584,2019-05-09 21:39:55 IST,2019-05-09,21:39:55,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,Wells Fargo $SGMO Hemo A #AA interest in enrollment is very high from the patient community $PFE Pfizer are also exploring #accelerated #approval path for SB-525  https://t.co/Z5gfFoE4OX,en,[],[],['https://pbs.twimg.com/media/D6IzqbgW4AAL8_c.jpg'],0,8,15,"['aa', 'accelerated', 'approval']","['sgmo', 'pfe']",https://twitter.com/_B_I_O_T_E_C_H_/status/1126519678015299584,False,,1,https://pbs.twimg.com/media/D6IzqbgW4AAL8_c.jpg,,,,,,,[],,,,
1126494251704045568,1126494251704045568,2019-05-09 19:58:53 IST,2019-05-09,19:58:53,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"$PFE and #Gene #Therapy: Preparing for ""Catastrophic Success"" Guggenheim hosted an event with Pfizer's Gene Therapy group to discuss the gene therapy landscape.... $SRPT $SGMO   https://t.co/Q3hNpEdiWS",en,[],['https://www.investorvillage.com/smbd.asp?mb=1933&mn=126318&pt=msg&mid=19406209'],[],5,4,19,"['gene', 'therapy']","['pfe', 'srpt', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/1126494251704045568,False,,0,,,,,,,,[],,,,
1126482057004298242,1126482057004298242,2019-05-09 19:10:26 IST,2019-05-09,19:10:26,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"$SGMO says treated first patient in the expansion group of #HEMOA study, with four more patients to be dosed in the group, and that interest in enrollment is very high from the patient community $PFE Pfizer are also exploring #accelerated #approval path for SB-525 ( $BMRN $ONCE )",en,[],[],[],1,6,8,"['hemoa', 'accelerated', 'approval']","['sgmo', 'pfe', 'bmrn', 'once']",https://twitter.com/_B_I_O_T_E_C_H_/status/1126482057004298242,False,,0,,,,,,,,[],,,,
1126082580158267392,1126082580158267392,2019-05-08 16:43:03 IST,2019-05-08,16:43:03,+0530,2274838086,biobonanos,Paul Bonanos,,"Pfizer is obtaining a clinical program to treat achondroplasia via its takeout of privately-held Therachon for $340 million up front plus $470 million in milestones. Versant, OrbiMed, Novo Holdings were among the privately held biotech's investors. $PFE  https://t.co/nS71eQvQzp",en,[],['https://www.biocentury.com/bc-extra/company-news/2019-05-08/therachon-takeout-pfizer-obtains-achondroplasia-program'],[],0,6,7,[],['pfe'],https://twitter.com/BioBonanos/status/1126082580158267392,False,,0,,,,,,,,[],,,,
1126076603266678784,1126076603266678784,2019-05-08 16:19:18 IST,2019-05-08,16:19:18,+0530,112872946,biostocks,Bio Stocks‚Ñ¢,,$PFE Pfizer Acquires Clinical-Stage Biotech Company Therachon For $340M Upfront With Additional $470M In Milestones  https://t.co/3oPq0YNx65,en,[],['https://www.businesswire.com/news/home/20190508005331/en/'],[],1,14,11,[],['pfe'],https://twitter.com/BioStocks/status/1126076603266678784,False,,0,,,,,,,,[],,,,
1123633976315453441,1123633976315453441,2019-05-01 22:33:10 IST,2019-05-01,22:33:10,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,@ #ASGCT19 Sangamo Therapeutics ( $SGMO) and partner Pfizer ( $PFE) presented data related to work on optimizing zinc finger nuclease (ZFN) transcription factors (TFs) to selectively repress expression of the C9ORF72 disease allele in amyotrophic lateral sclerosis (#ALS).  https://t.co/dIImvNQuXI,en,[],[],['https://pbs.twimg.com/media/D5fzGtlXoAAEq2S.jpg'],1,6,16,"['asgct19', 'als']","['sgmo', 'pfe']",https://twitter.com/_B_I_O_T_E_C_H_/status/1123633976315453441,False,,1,https://pbs.twimg.com/media/D5fzGtlXoAAEq2S.jpg,,,,,,,[],,,,
1123550288479182848,1123550288479182848,2019-05-01 17:00:37 IST,2019-05-01,17:00:37,+0530,223589965,gantosj,Joe,,"It's amazing to see the irrational reaction in $SRPT share price to any $PFE DMD news, while everyone knows well Pfizer is way back &amp; chances to beat the high bar set by $SRPT is slim. SRPT will be approved late 2020 &amp; own DMD market",en,[],[],[],0,2,29,[],"['srpt', 'pfe', 'srpt']",https://twitter.com/GantosJ/status/1123550288479182848,False,https://twitter.com/semodough/status/1123542021644476416,0,,,,,,,,[],,,,
1123500021830307841,1123500021830307841,2019-05-01 13:40:53 IST,2019-05-01,13:40:53,+0530,795618706743300096,biotech_junkie,Gene Editing,,$SRPT Mixed Commentary from $PFE Pfizer Call on Competitive Microdystrophin Program #DMD  baird CC @GantosJ  https://t.co/TOxYmmoylo,en,"[{'screen_name': 'gantosj', 'name': 'joe', 'id': '223589965'}]",[],"['https://pbs.twimg.com/media/D5d4_E3XoAAA3TW.jpg', 'https://pbs.twimg.com/media/D5d4_8wXsAE2EVb.jpg', 'https://pbs.twimg.com/media/D5d5AnXXsAEdMMf.jpg']",3,10,33,['dmd'],"['srpt', 'pfe']",https://twitter.com/biotech_junkie/status/1123500021830307841,False,,1,https://pbs.twimg.com/media/D5d4_E3XoAAA3TW.jpg,,,,,,,[],,,,
1123236158782226435,1123236158782226435,2019-04-30 20:12:23 IST,2019-04-30,20:12:23,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,$PFE PFIZER SAYS GENE THERAPY IS AN AREA OF SIGNIFICANT FOCUS FOR CO - CONF. CALL,en,[],[],[],2,3,10,[],['pfe'],https://twitter.com/_B_I_O_T_E_C_H_/status/1123236158782226435,False,,0,,,,,,,,[],,,,
1123235884797767681,1123235884797767681,2019-04-30 20:11:18 IST,2019-04-30,20:11:18,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"$PFE PFIZER WILL LOOK AT BOLT-ON DEALS OF ""A FEW BILLION DOLLARS"" TO COMPLEMENT PIPELINE - CONF. CALL",en,[],[],[],1,3,10,[],['pfe'],https://twitter.com/_B_I_O_T_E_C_H_/status/1123235884797767681,False,,0,,,,,,,,[],,,,
1123180938215677952,1123180938215677952,2019-04-30 16:32:58 IST,2019-04-30,16:32:58,+0530,913260122004086784,kessanman,Á±≥ÂõΩÊ†™ Ê±∫ÁÆó„Éû„É≥,,„Éï„Ç°„Ç§„Ç∂„ÉºÊ±∫ÁÆó Pfizer (NYSE:PFE) Q1'19 EPS(Non-GAAP) $0.85 ‰∫àÊÉ≥ +$0.10 Â£≤‰∏ä $13.12B (+1.6% Y/Y) ‰∫àÊÉ≥ +$110M  Ë£ΩËñ¨Â§ßÊâã„ÄÇNY„ÉÄ„Ç¶ÊßãÊàê‰ºÅÊ•≠„ÄÇÊ†™‰æ°„ÅØÊôÇÈñìÂ§ñ„Åß+1.8%  PDF:  https://t.co/6iQFDN5g4B  https://t.co/nsljkmD4ef,ja,[],['https://s21.q4cdn.com/317678438/files/doc_financials/Quarterly/2019/q1/Q1-2019-Earnings-Charts-FINAL.pdf'],['https://pbs.twimg.com/media/D5ZW_JaU0AIH7kY.png'],0,17,41,[],[],https://twitter.com/KessanMan/status/1123180938215677952,False,,1,https://pbs.twimg.com/media/D5ZW_JaU0AIH7kY.png,,,,,,,[],,,,
1121480978025807874,1121480978025807874,2019-04-25 23:57:55 IST,2019-04-25,23:57:55,+0530,151890124,iccronline,ICCR,,Over 28% of Pfizer ($PFE) shareholders just voted in favor of a report on the links between executive compensation and drug pricing risks - the highest vote yet for this 2nd year resolution - and a clear sign that investors see this as a material risk  https://t.co/nlWVTBYM9c,en,[],[],['https://pbs.twimg.com/media/D5BM402XsAArWoJ.jpg'],0,3,10,[],[],https://twitter.com/ICCRonline/status/1121480978025807874,False,,1,https://pbs.twimg.com/media/D5BM402XsAArWoJ.jpg,,,,,,,[],,,,
1119410120272826370,1119410120272826370,2019-04-20 06:49:04 IST,2019-04-20,06:49:04,+0530,102754598,johncendpts,John Carroll,,"Oh, yes -- top story today (only story today) RIP tanezumab? Eli Lilly, Pfizer spotlight alarming safety data for NGF pain drug in PhIII --See you Monday $PFE $LLY $REGN $TEVA  https://t.co/85hyVaPLgU",en,[],['https://endpts.com/rip-tanezumab-eli-lilly-pfizer-spotlight-alarming-safety-data-for-ngf-pain-drug-in-phiii/'],[],0,3,8,[],"['pfe', 'lly', 'regn', 'teva']",https://twitter.com/JohnCendpts/status/1119410120272826370,False,,0,,,,,,,,[],,,,
1118562893107056640,1118562893107056640,2019-04-17 22:42:30 IST,2019-04-17,22:42:30,+0530,49060415,tpetruno,Tom Petruno,,Today is a full-blown wipeout in healthcare stocks across the board. A few examples so far:  DaVita $DVA -7.1% Anthem $ANTM -5.9 Intuitive Surgical $ISRG -5.2 Biotech index $BTK -4.7 Cigna $CI -4.7 UnitedHealth $UNH -3.1 Merck $MRK -3.0 $CVS -2.7 Pfizer $PFE -2.5  S&amp;P 500 -0.1%,en,[],[],[],69,94,274,[],"['dva', 'antm', 'isrg', 'btk', 'ci', 'unh', 'mrk', 'cvs', 'pfe']",https://twitter.com/tpetruno/status/1118562893107056640,False,,0,,,,,,,,[],,,,
1114263825820332032,1114263825820332032,2019-04-06 01:59:32 IST,2019-04-06,01:59:32,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"$PFE Executive Outlines Vision for Treating Sickle Cell Disease, Other Rare Diseases ‚ÄúThe gene therapy people are looking at potentially 30 areas to move forward,‚Äù   ‚ÄúBut it‚Äôs very early in the process, so Pfizer doesn‚Äôt particularly talk about it.‚Äù $SGMO  https://t.co/ST78YXTUNO",en,[],['https://sicklecellanemianews.com/2019/04/04/pfizer-executive-outlines-vision-for-treating-sickle-cell-disease-other-rare-diseases/'],[],0,1,7,[],"['pfe', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/1114263825820332032,False,,0,,,,,,,,[],,,,
1113154255337213954,1113154255337213954,2019-04-03 00:30:30 IST,2019-04-03,00:30:30,+0530,3426014292,semodough,dough,,"ISI $PFE $SGMO Factor 8 gene tx starting to ""work"" There was an impt update by Sangamo this morning which may have flown under the radar for Pfizer investors-Given focus on Pfizer's pipeline of late, we thought its impt to flag.",en,[],[],[],1,3,12,[],"['pfe', 'sgmo']",https://twitter.com/semodough/status/1113154255337213954,False,,0,,,,,,,,[],,,,
1113064009236799489,1113064009236799489,2019-04-02 18:31:54 IST,2019-04-02,18:31:54,+0530,102754598,johncendpts,John Carroll,,Sangamo bounces back with upbeat snapshot on hem A allied with Pfizer and a plan to beef up AAV manufacturing $SGMO +51% $PFE  https://t.co/2elGtrkQmx,en,[],['https://endpts.com/sangamo-bounces-back-with-upbeat-data-on-hem-a-allied-with-pfizer-and-a-plan-to-beef-up-aav-manufacturing/'],[],1,16,33,[],"['sgmo', 'pfe']",https://twitter.com/JohnCendpts/status/1113064009236799489,False,,0,,,,,,,,[],,,,
1111758697661894657,1111758697661894657,2019-03-30 04:05:03 IST,2019-03-30,04:05:03,+0530,227778014,biocentury,BioCentury,,Pfizer's ketohexokinase inhibitor decreases liver fat content in Phase II for NAFLD $PFE  https://t.co/exutZpZfkX,ro,[],['https://buff.ly/2HNFQru'],[],0,1,4,[],['pfe'],https://twitter.com/BioCentury/status/1111758697661894657,False,,0,,,,,,,,[],,,,
1111394024555008000,1111394024555008000,2019-03-29 03:55:58 IST,2019-03-29,03:55:58,+0530,142384766,floszcrxl,flosz,,"Intellectual property: Our proprietary analysis of the Simioni patent estate gives us conviction that $QURE can have blocking IP among Padua variant FIX AAV GT competitors, including Spark/Pfizer $ONCE $PFE and Freeline.  https://t.co/9XeJFHYIvb  https://t.co/9JS1co1JWY",en,[],['https://www.iex.nl/Forum/Topic/1286603/335/Wat-is-de-waarde-van-uniQure.aspx#11511931'],['https://pbs.twimg.com/media/D2x2-EFXcAA-ZRJ.jpg'],1,4,11,[],"['qure', 'once', 'pfe']",https://twitter.com/floszcrxl/status/1111394024555008000,False,,1,https://pbs.twimg.com/media/D2x2-EFXcAA-ZRJ.jpg,,,,,,,[],,,,
1109483375088336896,1109483375088336896,2019-03-23 21:23:44 IST,2019-03-23,21:23:44,+0530,102754598,johncendpts,John Carroll,,#4 How hot are gene therapies? Pfizer lines up a potential $687M rare disease buyout to expand its stake in the hot gene therapy field $PFE  https://t.co/vCZUT6QTcK,en,[],['https://endpts.com/pfizer-lines-up-a-potential-687m-rare-disease-buyout-to-expand-its-stake-in-the-hot-gene-therapy-field/'],[],0,4,8,[],['pfe'],https://twitter.com/JohnCendpts/status/1109483375088336896,False,,0,,,,,,,,[],,,,
1108425395685085184,1108425395685085184,2019-03-20 23:19:42 IST,2019-03-20,23:19:42,+0530,2848493747,jeff_cranmer,Jeff Cranmer,,$PFE deal w/France's Vivet is at least its 5th disclosed #genetherapy deal in past 3 years. Pfizer has option to buy after Ph I/II of Vivet's Wilson disease therapy. Story in @BioCentury Extra:  https://t.co/oUTYezUp6a,en,"[{'screen_name': 'biocentury', 'name': 'biocentury', 'id': '227778014'}]",['https://www.biocentury.com/bc-extra/company-news/2019-03-20/pfizer-gains-option-buy-liver-gene-therapy-company-vivet'],[],1,5,5,['genetherapy'],['pfe'],https://twitter.com/jeff_cranmer/status/1108425395685085184,False,,0,,,,,,,,[],,,,
1108331463609643008,1108331463609643008,2019-03-20 17:06:27 IST,2019-03-20,17:06:27,+0530,102754598,johncendpts,John Carroll,,Laiisez les bon temps rouler -- Pfizer lines up a potential $687M rare disease buyout to expand its stake in the hot gene therapy field $PFE  https://t.co/vCZUT6QTcK,en,[],['https://endpts.com/pfizer-lines-up-a-potential-687m-rare-disease-buyout-to-expand-its-stake-in-the-hot-gene-therapy-field/'],[],0,4,8,[],['pfe'],https://twitter.com/JohnCendpts/status/1108331463609643008,False,,0,,,,,,,,[],,,,
1105214384534683648,1105214384534683648,2019-03-12 02:40:17 IST,2019-03-12,02:40:17,+0530,13171622,pharmalot,pharmalot,,"Pfizer agrees to pay $975,000 to settle charges over misleading co-pay coupons.. 2nd time in five months..  https://t.co/ikrVvkCOQk #pharma $PFE #coupons",en,[],['https://www.statnews.com/pharmalot/2019/03/11/pfizer-settlement-copay-coupons/'],[],0,2,5,"['pharma', 'coupons']",['pfe'],https://twitter.com/pharmalot/status/1105214384534683648,False,,0,,,,,,,,[],,,,
1102561510763753472,1102561510763753472,2019-03-04 18:58:43 IST,2019-03-04,18:58:43,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"$PFE PFIZER INC FILES FOR POTENTIAL, 5-PART NOTES OFFERING; SIZE NOT DISCLOSED - SEC FILING",en,[],[],[],1,1,6,[],['pfe'],https://twitter.com/_B_I_O_T_E_C_H_/status/1102561510763753472,False,,0,,,,,,,,[],,,,
1100391305757233152,1100391305757233152,2019-02-26 19:15:06 IST,2019-02-26,19:15:06,+0530,25998862,drugchannels,Adam J. Fein,,"Must watch TV! Today at 10:15 AM, @SenateFinance hearing on ""Drug Pricing in America"" with @abbvie $ABBV, @AstraZeneca $AZN, @bmsnews $BMS, @JanssenUS $JNJ, @Merck $MRK, @pfizer $PFE, and @SanofiUS $SNY.  https://t.co/jUH9TJ5rLV  P.S. Over/under on use of ""skyrocketing"" = 42  https://t.co/uxBL775ztK",en,"[{'screen_name': 'senatefinance', 'name': 'senate finance cmte', 'id': '628709039'}, {'screen_name': 'abbvie', 'name': 'abbvie', 'id': '531892451'}, {'screen_name': 'astrazeneca', 'name': 'astrazeneca', 'id': '62465691'}, {'screen_name': 'bmsnews', 'name': 'bristol myers squibb', 'id': '34010976'}, {'screen_name': 'janssenus', 'name': 'janssenus', 'id': '256182836'}, {'screen_name': 'merck', 'name': 'merck', 'id': '35961145'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'sanofius', 'name': 'sanofi us', 'id': '183033795'}]",['https://drugch.nl/2Vic8NR'],['https://pbs.twimg.com/media/D0VgD50XQAMNf8R.jpg'],1,3,11,[],"['abbv', 'azn', 'bms', 'jnj', 'mrk', 'pfe', 'sny']",https://twitter.com/DrugChannels/status/1100391305757233152,False,,1,https://pbs.twimg.com/media/D0VgD50XQAMNf8R.jpg,,,,,,,[],,,,
1098181206267580416,1098181206267580416,2019-02-20 16:52:57 IST,2019-02-20,16:52:57,+0530,102754598,johncendpts,John Carroll,,"Pfizer drops 10 mg dose of best-selling Xeljanz as study spotlights cardio safety issue, higher rate of deaths $PFE  https://t.co/k8z53NTTDy",de,[],['https://endpts.com/pfizer-study-drops-10-mg-dose-of-best-selling-xeljanz-as-safety-study-spotlights-cardio-safety-questions-higher-rate-of-deaths/'],[],1,10,16,[],['pfe'],https://twitter.com/JohnCendpts/status/1098181206267580416,False,,0,,,,,,,,[],,,,
1097462309780217858,1097462309780217858,2019-02-18 17:16:19 IST,2019-02-18,17:16:19,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"Thursday 16th May 2019 IN VIVO GENE THERAPY  14:15 Presentation Bob Smith, SVP, Global Gene Therapy Business, Rare Disease, Global Innovative Pharma, $PFE Pfizer (TBC) $SGMO ... hemophiliaA",en,[],[],[],0,3,10,[],"['pfe', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/1097462309780217858,False,,0,,,,,,,,[],,,,
1094087427302387713,1094087427302387713,2019-02-09 09:45:44 IST,2019-02-09,09:45:44,+0530,1065422151006674944,stockplays,PlayZwithStockZ,,#Pfizer Japan recalls high blood pressure drug over cancer-causing impurity...  #Drugs have too many side effects. #CaverStem and #FemCelz are drug free procedures for sexual dysfunction.   https://t.co/kyVjAmvfWH  $PFE $CELZ $MRK $LLY $RHHBY @pfizer @Merck @LillyPad @abbvie,en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'merck', 'name': 'merck', 'id': '35961145'}, {'screen_name': 'lillypad', 'name': 'eli lilly and company', 'id': '172496840'}, {'screen_name': 'abbvie', 'name': 'abbvie', 'id': '531892451'}]",['https://www.yahoo.com/finance/news/pfizer-japan-recalls-high-blood-144354662.html'],[],0,5,10,"['pfizer', 'drugs', 'caverstem', 'femcelz']","['pfe', 'celz', 'mrk', 'lly', 'rhhby']",https://twitter.com/StockPlays/status/1094087427302387713,False,,0,,,,,,,,[],,,,
1093201773517590528,1093201773517590528,2019-02-06 23:06:28 IST,2019-02-06,23:06:28,+0530,42782695,berkeleyjr,Berkeley Lovelace,,Lawmakers released letters inviting 7 major pharma companies to testify about drug prices this month. So far:  ‚Ä¢ Pfizer $PFE: Yes ‚Ä¢ Merck $MRK: Yes ‚Ä¢ Sanofi $SNY: Yes ‚Ä¢ Bristol $BMY: Yes ‚Ä¢ AstraZeneca $AZN: Reviewing request   https://t.co/m3cInY63mp‚Ä¶ w/ @angelicalavito,en,"[{'screen_name': 'angelicalavito', 'name': 'angelicalavito', 'id': '550112968'}]",['http://cnbc.com/2019/02/06/7-d'],[],1,6,13,[],"['pfe', 'mrk', 'sny', 'bmy', 'azn']",https://twitter.com/BerkeleyJr/status/1093201773517590528,False,,0,,,,,,,,[],,,,
1091380239773487104,1090669018028130309,2019-02-01 22:28:20 IST,2019-02-01,22:28:20,+0530,2910321650,mihotep,"Dr. Johnny Twovapes, VBOSB",,@JeromeAdamsMD @McKenzieCox14 @OverBadWater @Geoffsabtchange @Surgeon_General @SGottliebFDA @LaurieScudderNP @Medscape Hmm. I think that's Pfizer $PFE  https://t.co/Lx3zG2UJjo,en,[],[],['https://pbs.twimg.com/media/DyVcikNUUAE3zp_.jpg'],0,0,9,[],['pfe'],https://twitter.com/mihotep/status/1091380239773487104,False,,1,https://pbs.twimg.com/media/DyVcikNUUAE3zp_.jpg,,,,,,,"[{'screen_name': 'JeromeAdamsMD', 'name': 'Jerome Adams', 'id': '488950348'}, {'screen_name': 'McKenzieCox14', 'name': 'McKenzie Cox', 'id': '1236786261341409281'}, {'screen_name': 'OverBadWater', 'name': 'The Bridge', 'id': '1083180058225885184'}, {'screen_name': 'Geoffsabtchange', 'name': 'GeoffHenderson', 'id': '50804274'}, {'screen_name': 'Surgeon_General', 'name': 'Dr. Vivek Murthy, 21st U.S. Surgeon General', 'id': '455024343'}, {'screen_name': 'LaurieScudderNP', 'name': 'Laurie Scudder', 'id': '347959055'}, {'screen_name': 'Medscape', 'name': 'Medscape', 'id': '16892009'}]",,,,
1090270742858461185,1090270742858461185,2019-01-29 20:59:36 IST,2019-01-29,20:59:36,+0530,21328656,ibdinvestors,Investors.com,,"Stocks Mixed: Apple Earnings Due, Pfizer Reports, Pinduoduo Strong $AAPL $PFE $PDD  https://t.co/E22wK0njkp",en,[],['https://www.pscp.tv/w/byBo3zFkclFla1dEZU5namJ8MU1ueG5OZ0Jrem14T8wUm8U8wBu4NTc3K6Ih5ybBrNnaJSkbv0mv5amMz5_M'],[],0,3,8,[],"['aapl', 'pfe', 'pdd']",https://twitter.com/IBDinvestors/status/1090270742858461185,False,,0,,,,,,,,[],,,,
1090218454685085697,1090218454685085697,2019-01-29 17:31:49 IST,2019-01-29,17:31:49,+0530,913260122004086784,kessanman,Á±≥ÂõΩÊ†™ Ê±∫ÁÆó„Éû„É≥,,„Éï„Ç°„Ç§„Ç∂„ÉºÊ±∫ÁÆó Pfizer (NYSE:PFE) Q4 EPS(Non-GAAP) $0.64 ‰∫àÊÉ≥ +$0.01 Â£≤‰∏ä $13.98B (+2.0% Y/Y) ‰∫àÊÉ≥ +$80M  FY2019„Ç¨„Ç§„ÉÄ„É≥„Çπ Â£≤‰∏ä $52BÔΩû$54B EPS $2.82ÔΩû$2.92  „ÉÄ„Ç¶ÊßãÊàê„ÅÆË£ΩËñ¨‰ºÅÊ•≠„ÄÄÊ†™‰æ°„ÅØÊôÇÈñìÂ§ñ„Åß-2.3%  IR PDF:  https://t.co/UOZGTptFqm  https://t.co/RdKlgN8h1j,ja,[],['https://s21.q4cdn.com/317678438/files/doc_financials/Quarterly/2018/q4/Q4-2018-PFE-Earnings-Release.pdf'],['https://pbs.twimg.com/media/DyE75QPV4AE12bh.jpg'],0,19,25,[],[],https://twitter.com/KessanMan/status/1090218454685085697,False,,1,https://pbs.twimg.com/media/DyE75QPV4AE12bh.jpg,,,,,,,[],,,,
1090214821646254081,1090214821646254081,2019-01-29 17:17:23 IST,2019-01-29,17:17:23,+0530,59393368,livesquawk,LiveSquawk,,Pfizer Q4 Earnings: $PFE -Revenue: $13.976B (est $13.703B) -Adj EPS: 64C (est 63C) -Sees FY Adj EPS: $2.82-$2.92 (est $3.64) -Sees FY Rev: $52.08-$54.08 (est $54.27B) -Sees Repurchasing Of $9Bln Of Shares In 2019,en,[],[],[],0,17,16,[],['pfe'],https://twitter.com/LiveSquawk/status/1090214821646254081,False,,0,,,,,,,,[],,,,
1088924175442591745,1088924175442591745,2019-01-26 03:48:49 IST,2019-01-26,03:48:49,+0530,227778014,biocentury,BioCentury,,Pfizer launches China's first pay-for-performance model for cancer   https://t.co/HF225Zzt2X $PFE #Ibrance,en,[],['https://buff.ly/2CKCSyR'],[],0,12,15,['ibrance'],['pfe'],https://twitter.com/BioCentury/status/1088924175442591745,False,,0,,,,,,,,[],,,,
1088080390806478854,1088080390806478854,2019-01-23 19:55:55 IST,2019-01-23,19:55:55,+0530,582314623,auricgoldfinqer,Auric,,"UBS slashed Pfizer's rating to neutral from buy on Wednesday, citing the  so-called ""patent cliff"" in the coming years on key products that would  greatly offset revenue growth. Free advice for PFE... $SRPT",en,[],[],[],0,1,16,[],['srpt'],https://twitter.com/AuricGoldFinqer/status/1088080390806478854,False,,0,,,,,,,,[],,,,
1087793556788600832,1087793556788600832,2019-01-23 00:56:08 IST,2019-01-23,00:56:08,+0530,320304156,investimenti_it,Mercati Investimenti,,"Pfizer and Intel are working on supply chain visibility (PFE, INTC) This story was delivered to Business Insider Intelligence Transportation &amp; Logistics Briefing subscribers hours before it appeared on Bu...  https://t.co/CGvA55KEG5  https://t.co/sle0TuzYfT",en,[],['https://www.businessinsider.com/pfizer-intel-supply-chain-visibility-2018-12'],['https://pbs.twimg.com/media/DxieeZCUUAADByi.jpg'],0,0,0,[],[],https://twitter.com/Investimenti_IT/status/1087793556788600832,False,,1,https://pbs.twimg.com/media/DxieeZCUUAADByi.jpg,,,,,,,[],,,,
1084950139364671488,1084950139364671488,2019-01-15 04:37:25 IST,2019-01-15,04:37:25,+0530,26368450,pearlf,Pearl Freier,,Pfizer's Barbara Dalton &amp; Denis Patrick discussed Pfizer's 2019 funding strategy for neuroscience w/ @erbrod @businessinsider. Allocation of up to $150M to invest in neuro-focused biotechs ranging from mid-to-late-stage.  https://t.co/878edVyTIv ht @ZTracer $PFE,en,"[{'screen_name': 'erbrod', 'name': 'erin brodwin ‚ö°', 'id': '74292666'}, {'screen_name': 'businessinsider', 'name': 'business insider', 'id': '20562637'}, {'screen_name': 'ztracer', 'name': 'zachary tracer', 'id': '14622223'}]",['https://read.bi/2MbSIH9'],[],1,2,5,[],['pfe'],https://twitter.com/PearlF/status/1084950139364671488,False,,0,,,,,,,,[],,,,
1084945241277427713,1084945241277427713,2019-01-15 04:17:57 IST,2019-01-15,04:17:57,+0530,16732770,cnbcfastmoney,CNBC's Fast Money,,'@petenajarian sees healthy gains ahead for Pfizer. Here's his fast pitch for the stock $PFE  https://t.co/J6pCocJHS7,en,"[{'screen_name': 'petenajarian', 'name': 'pete najarian', 'id': '14292717'}]",[],[],6,7,32,[],['pfe'],https://twitter.com/CNBCFastMoney/status/1084945241277427713,False,,1,https://pbs.twimg.com/media/Dw5_8ZKWoAAlBK2.jpg,,,,,,,[],,,,
1084914114370121729,1084914114370121729,2019-01-15 02:14:16 IST,2019-01-15,02:14:16,+0530,102754598,johncendpts,John Carroll,,Scoop: Pfizer once again takes out the budget ax and lops off 150 R&amp;D staffers and 5 preclinical biosimilar drugs $PFE  https://t.co/qKFNoo2toH,en,[],['https://endpts.com/pfizer-once-again-takes-out-the-budget-ax-and-lops-off-150-staffers-and-5-preclinical-biosimilar-drugs/'],[],1,5,7,[],['pfe'],https://twitter.com/JohnCendpts/status/1084914114370121729,False,,0,,,,,,,,[],,,,
1084879260651843586,1084860377828126720,2019-01-14 23:55:46 IST,2019-01-14,23:55:46,+0530,42782695,berkeleyjr,Berkeley Lovelace,,The 12 companies that the panel requested information from:  AbbVie $ABBV Amgen $AMGN AstraZeneca $AZN Celgene $CELG Eli Lilly $LLY Johnson &amp; Johnson $JNJ Mallinckrodt $MNK Novartis $NVS Novo Nordisk $NVO Pfizer $PFE Sanofi $SNY Teva Pharmaceuticals $TEVA,en,[],[],[],1,3,6,[],"['abbv', 'amgn', 'azn', 'celg', 'lly', 'jnj', 'mnk', 'nvs', 'nvo', 'pfe', 'sny', 'teva']",https://twitter.com/BerkeleyJr/status/1084879260651843586,False,,0,,,,,,,,[],,,,
1083387439698399232,1083387439698399232,2019-01-10 21:07:48 IST,2019-01-10,21:07:48,+0530,1469603575,qtrresearch,Quoth the Raven,,$AMRN Amarin Corp. (NASDAQ: AMRN) is seeing early strength on renewed takeover chatter. Rumors today suggested Pfizer (NYSE: $PFE) could be interested in the company. Shares are up 7%. - via Street Insider  (h/t @OpenOutcrier),en,"[{'screen_name': 'openoutcrier', 'name': 'open outcrier', 'id': '2334614718'}]",[],[],4,17,33,[],"['amrn', 'pfe']",https://twitter.com/QTRResearch/status/1083387439698399232,False,,0,,,,,,,,[],,,,
1083044578222051328,1083044578222051328,2019-01-09 22:25:24 IST,2019-01-09,22:25:24,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,Dear @GileadSciences @abbvie @pfizer @Celgene @Roche  Sangamo will have HIV clinical data readout within 2 months.  Are you interested in an HIV Cure option? @SangamoTx wants to partner this pipeline.  https://t.co/u0bn7x2bvO  $SGMO $GILD $ABBV $PFE $CELG #JPM19,en,"[{'screen_name': 'gileadsciences', 'name': 'gilead sciences', 'id': '309728693'}, {'screen_name': 'abbvie', 'name': 'abbvie', 'id': '531892451'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'roche', 'name': 'roche', 'id': '20815041'}, {'screen_name': 'sangamotx', 'name': 'sangamo therapeutics', 'id': '809083633671643136'}]",['https://clinicaltrials.gov/ct2/show/NCT02500849'],[],0,2,13,['jpm19'],"['sgmo', 'gild', 'abbv', 'pfe', 'celg']",https://twitter.com/Biotech2050/status/1083044578222051328,False,,0,,,,,,,,[],,,,
1082739643441967107,1082739643441967107,2019-01-09 02:13:41 IST,2019-01-09,02:13:41,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,$PFE Pfizer speaking about SangamoTherapeutics at #JPM19  https://t.co/5iFHChWsQJ,en,[],[],[],0,9,18,['jpm19'],['pfe'],https://twitter.com/_B_I_O_T_E_C_H_/status/1082739643441967107,False,,1,https://pbs.twimg.com/ext_tw_video_thumb/1082739522046255104/pu/img/NerA9f_R9plZP1CE.jpg,,,,,,,[],,,,
1080839234523750400,1080839234523750400,2019-01-03 20:22:09 IST,2019-01-03,20:22:09,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,What happens now: 1. $PFE buys $GILD &amp; $SGMO 2. $PFE screws $BMY and makes a better offer for $CELG as it realizes that CC-92480 + CC-220 + BCMA will more than replenish revlimid patent hill  @pfizer @Celgene @bmsnews @GileadSciences @SangamoTx,en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'bmsnews', 'name': 'bristol myers squibb', 'id': '34010976'}, {'screen_name': 'gileadsciences', 'name': 'gilead sciences', 'id': '309728693'}, {'screen_name': 'sangamotx', 'name': 'sangamo therapeutics', 'id': '809083633671643136'}]",[],[],0,3,7,[],"['pfe', 'gild', 'sgmo', 'pfe', 'bmy', 'celg']",https://twitter.com/Biotech2050/status/1080839234523750400,False,,0,,,,,,,,[],,,,
1080785112718065665,1080785112718065665,2019-01-03 16:47:05 IST,2019-01-03,16:47:05,+0530,3426014292,semodough,dough,,CS estimate that Sarepta‚Äôs DMD gene therapy remains ~9-12 months ahead of Pfizer‚Äôs program and potentially ~12-18+ months ahead of Solid‚Äôs product development $SRPT $PFE  https://t.co/RCiZLewH5Q,en,[],[],['https://pbs.twimg.com/media/Dv-4VA1UYAEU_UL.jpg'],1,6,27,[],"['srpt', 'pfe']",https://twitter.com/semodough/status/1080785112718065665,False,,1,https://pbs.twimg.com/media/Dv-4VA1UYAEU_UL.jpg,,,,,,,[],,,,
1075310359018393601,1075310359018393601,2018-12-19 14:12:22 IST,2018-12-19,14:12:22,+0530,5383942,gsk,GSK,,"Join Emma Walmsley, Brian McNamara and Simon Dingemans at 09:00 GMT, 04:00 EST for our investor call on our agreement with @Pfizer to form a new world-leading Consumer Healthcare Joint Venture $GSK $PFE",en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}]",[],[],0,10,26,[],"['gsk', 'pfe']",https://twitter.com/GSK/status/1075310359018393601,False,,0,,,,,,,,[],,,,
1075290390167736320,1075288454454501376,2018-12-19 12:53:01 IST,2018-12-19,12:53:01,+0530,5383942,gsk,GSK,,"The new world-leading Joint Venture will combine @GSK and @Pfizer‚Äôs consumer health businesses, with combined sales of approximately ¬£9.8bn.  Read more:  https://t.co/Plp3M8O78e $GSK $PFE  https://t.co/zKAvdP1DTH",en,"[{'screen_name': 'gsk', 'name': 'gsk', 'id': '5383942'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}]",['https://gsk.to/2Ewllgg'],['https://pbs.twimg.com/media/Duwy6TWWwAAgjeh.jpg'],1,19,16,[],"['gsk', 'pfe']",https://twitter.com/GSK/status/1075290390167736320,False,,1,https://pbs.twimg.com/media/Duwy6TWWwAAgjeh.jpg,,,,,,,[],,,,
1075288454454501376,1075288454454501376,2018-12-19 12:45:20 IST,2018-12-19,12:45:20,+0530,5383942,gsk,GSK,,"#NEWS: Today, we have reached an agreement with @Pfizer to form a new world-leading Consumer Healthcare Joint Venture.   Read more:  https://t.co/a5Cfg5A75H $GSK $PFE  https://t.co/dxRgCMax0w",en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}]",['https://gsk.to/2EEJ1Ad'],[],15,114,224,['news'],"['gsk', 'pfe']",https://twitter.com/GSK/status/1075288454454501376,False,,1,https://pbs.twimg.com/amplify_video_thumb/1075288018519539712/img/4ey5L_JDFPeDDIYY.jpg,,,,,,,[],,,,
1075161636716072960,1075161636716072960,2018-12-19 04:21:24 IST,2018-12-19,04:21:24,+0530,326315947,optionsaction,Options Action,,"Pfizer shares have cooled with the rest of health care, but one trader is betting on a bouce ahead. @RiskReversal breaks down the trade $PFE  https://t.co/bvRTno1j2d",en,"[{'screen_name': 'riskreversal', 'name': 'dan nathan', 'id': '271211220'}]",[],[],1,3,11,[],['pfe'],https://twitter.com/OptionsAction/status/1075161636716072960,False,,1,https://pbs.twimg.com/media/Duu9zW-WoAIw5OZ.jpg,,,,,,,[],,,,
1074575151818256384,1074575151818256384,2018-12-17 13:30:55 IST,2018-12-17,13:30:55,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,Dear @pfizer @NovartisScience @Celgene @sanofi @GileadSciences $PFE $GILD $CELG $NVS $SNY $SGMO has a new pipeline which could be very disruptive: CAR-Tregs for #autoimmune disorders and organ rejection. This article explains the potential. #WinterIsComing  https://t.co/YHVdcFsF0v,en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'novartisscience', 'name': 'novartis science', 'id': '2260514101'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'sanofi', 'name': 'sanofi', 'id': '35846368'}, {'screen_name': 'gileadsciences', 'name': 'gilead sciences', 'id': '309728693'}]",['https://singularityhub.com/2018/08/07/car-t-may-be-a-silver-bullet-against-cancer-and-heres-what-else-it-can-do/#sm.0000vcl47c1cvqcx6rhy2t9ilq314'],[],1,2,5,"['autoimmune', 'winteriscoming']","['pfe', 'gild', 'celg', 'nvs', 'sny', 'sgmo']",https://twitter.com/Biotech2050/status/1074575151818256384,False,,0,,,,,,,,[],,,,
1073626695746375680,1073626695746375680,2018-12-14 22:42:05 IST,2018-12-14,22:42:05,+0530,801116888,cfromhertz,Christian Fromhertz,,"$PFE  *PFIZER AUTHORIZES NEW $10B SHARE BUYBACK PROGRAM *PFIZER BOOSTS QTR DIV/SHR TO 36C FROM 34C, EST. 36C",de,[],[],[],0,6,13,[],['pfe'],https://twitter.com/cfromhertz/status/1073626695746375680,False,,0,,,,,,,,[],,,,
1072591272177733632,1072591272177733632,2018-12-12 02:07:41 IST,2018-12-12,02:07:41,+0530,13171622,pharmalot,pharmalot,,Lawmaker chastises Pfizer ceo Ian Read for reverting to price hikes next month... what will he say?  https://t.co/e7AoocqFS7 #pharma #Trump #drugprices $PFE,en,[],['https://www.statnews.com/pharmalot/2018/12/11/pfzier-price-hikes-letter-baldwin/'],[],2,2,5,"['pharma', 'trump', 'drugprices']",['pfe'],https://twitter.com/pharmalot/status/1072591272177733632,False,,0,,,,,,,,[],,,,
1068532232564944897,1068532232564944897,2018-11-30 21:18:31 IST,2018-11-30,21:18:31,+0530,15563814,loftus,Peter Loftus,,"Pfizer becomes 7th drugmaker to reach deal with AbbVie to sell biosimilar version of Humira, agreeing to wait until 2023 to launch in U.S. $PFE $ABBV",en,[],[],[],4,18,26,[],"['pfe', 'abbv']",https://twitter.com/Loftus/status/1068532232564944897,False,,0,,,,,,,,[],,,,
1068150147304079362,1068150147304079362,2018-11-29 20:00:15 IST,2018-11-29,20:00:15,+0530,475309726,tradestation,TradeStation,,"Tech may have earned the headlines lately, but the #pharmaceutical sector seems to be luring the bulls. Take a look at charts from #bigpharma companies like #Pfizer $PFE, #Merck $MRK and #Amgen $AMGN.  https://t.co/My1iOz6AQC  https://t.co/fGkvbCDsqh",en,[],['https://bit.ly/2DPmsaG'],['https://pbs.twimg.com/media/DtLU5dhXgAs7Clt.jpg'],1,7,69,"['pharmaceutical', 'bigpharma', 'pfizer', 'merck', 'amgen']","['pfe', 'mrk', 'amgn']",https://twitter.com/TradeStation/status/1068150147304079362,False,,1,https://pbs.twimg.com/media/DtLU5dhXgAs7Clt.jpg,,,,,,,[],,,,
1067824381773135873,1067824381773135873,2018-11-28 22:25:46 IST,2018-11-28,22:25:46,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,Hi @pfizer  With the acquisition of @TxCellSA now $SGMO can apply its zinc finger platform in combo with CAR T Regs and target autoimmune diseases and #diabetes type 1  If $pfe wants a cure then its time to make another deal with @SangamoTx  (psst is $GILD making a buyout offer?),en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'sangamotx', 'name': 'sangamo therapeutics', 'id': '809083633671643136'}]",[],[],1,3,10,['diabetes'],"['sgmo', 'pfe', 'gild']",https://twitter.com/Biotech2050/status/1067824381773135873,False,https://twitter.com/pfizer/status/1067822708086513664,0,,,,,,,,[],,,,
1066987477829935105,1066987477829935105,2018-11-26 15:00:13 IST,2018-11-26,15:00:13,+0530,3460109487,endpts,Endpoints News,,"Playing a hot hand in #cancer R&amp;D, Pfizer scores its 4th drug approval in just 2 months  https://t.co/6sloGovVEw $PFE",en,[],['https://endpts.com/playing-a-hot-hand-in-cancer-rd-pfizer-scores-its-4th-drug-approval-in-just-2-months/'],[],0,1,10,['cancer'],['pfe'],https://twitter.com/endpts/status/1066987477829935105,False,,0,,,,,,,,[],,,,
1065312267208667136,1065312267208667136,2018-11-22 00:03:31 IST,2018-11-22,00:03:31,+0530,632341632,andybiotech,Andy Biotech,,"DAURISMO (glasdegib) also marks $PFE's 4th FDA-approved NME oncology drug in less than 2 months, quite an accomplishment from @pfizer!   VIZIMPRO (dacomitinib) TALZENNA (talazoparib) LORBRENA (lorlatinib) DAURISMO (glasdegib)",en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}]",[],[],2,8,22,[],['pfe'],https://twitter.com/AndyBiotech/status/1065312267208667136,False,,0,,,,,,,,[],,,,
1065246443919851521,1065246443919851521,2018-11-21 19:41:58 IST,2018-11-21,19:41:58,+0530,102754598,johncendpts,John Carroll,,Pfizer wants to reel back contributions to Hyde-Smith after her remarks about ‚Äòpublic hanging‚Äô spark controversy $PFE  https://t.co/992HfmXIjp,en,[],['https://endpts.com/pfizer-wants-to-reel-back-contributions-to-hyde-smith-after-her-remarks-about-public-hanging-spark-controversy/'],[],0,1,5,[],['pfe'],https://twitter.com/JohnCendpts/status/1065246443919851521,False,,0,,,,,,,,[],,,,
1063334473918554112,1063334473918554112,2018-11-16 13:04:29 IST,2018-11-16,13:04:29,+0530,810777649157128192,immunicum,Immunicum AB,,"Today we announced our first collaboration agreement, with Merck KGaA $MKGAF and Pfizer $PFE to evaluate our lead product ilixadencel in combination with the checkpoint inhibitor avelumab in the planned Phase Ib/II ILIAD study. For more info, visit  https://t.co/AcpevHiZmU  https://t.co/AOfMzMDCPM",en,[],['http://bit.ly/2DFm0g3'],['https://pbs.twimg.com/media/DsG5AH8XoAE_RP_.png'],0,11,19,[],"['mkgaf', 'pfe']",https://twitter.com/Immunicum/status/1063334473918554112,False,,1,https://pbs.twimg.com/media/DsG5AH8XoAE_RP_.png,,,,,,,[],,,,
1062707983258398720,1062707983258398720,2018-11-14 19:35:02 IST,2018-11-14,19:35:02,+0530,2419044359,jessicaemerrill,Jessica Merrill,,"$PFE has launched Retacrit, the first# biosimilar of $AMGN's #Epogen (epoetin alfa) in the US, now Pfizer's third marketed biosimilar. Price is 33.5% of the WAC of Epogen, not including discounts.",en,[],[],[],1,6,7,['epogen'],"['pfe', 'amgn']",https://twitter.com/Jessicaemerrill/status/1062707983258398720,False,,0,,,,,,,,[],,,,
1058707477594861568,1058707477594861568,2018-11-03 18:38:27 IST,2018-11-03,18:38:27,+0530,102754598,johncendpts,John Carroll,,"Pfizer racks up its third cancer drug OK in 2 months, but is it enough to replace regular price hikes? $PFE  https://t.co/ib1Hg1hJED",en,[],['https://endpts.com/pfizer-racks-up-its-third-cancer-drug-ok-in-2-months-but-is-it-enough-to-replace-regular-price-hikes/'],[],2,1,9,[],['pfe'],https://twitter.com/JohnCendpts/status/1058707477594861568,False,,0,,,,,,,,[],,,,
1057237013445767168,1057237013445767168,2018-10-30 17:15:21 IST,2018-10-30,17:15:21,+0530,913260122004086784,kessanman,Á±≥ÂõΩÊ†™ Ê±∫ÁÆó„Éû„É≥,,„Éï„Ç°„Ç§„Ç∂„ÉºÊ±∫ÁÆó Pfizer (NYSE:PFE) Q3 EPS $0.78 ‰∫àÊÉ≥ +$0.03 Â£≤‰∏ä $13.3B (+1.0% Y/Y) ‰∫àÊÉ≥ -$230M  Ë£ΩËñ¨Â§ßÊâã„ÄÇ„ÉÄ„Ç¶ÊßãÊàê‰ºÅÊ•≠„ÄÇ  FY2018„Ç¨„Ç§„ÉÄ„É≥„Çπ„Åå‰∏ãÊñπ‰øÆÊ≠£„Åï„Çå„ÄÅÊ†™‰æ°„ÅØÊôÇÈñìÂ§ñ„Åß-3.7%  PDF:  https://t.co/SpGPmcHdlr  https://t.co/LIQPaaWd5x,ja,[],['https://s21.q4cdn.com/317678438/files/doc_financials/Quarterly/2018/q3/Q3-2018-PFE-Earnings-Release.pdf'],['https://pbs.twimg.com/media/DqwPY4mVYAANGhO.jpg'],0,19,22,[],[],https://twitter.com/KessanMan/status/1057237013445767168,False,,1,https://pbs.twimg.com/media/DqwPY4mVYAANGhO.jpg,,,,,,,[],,,,
1057231736864731136,1057231736864731136,2018-10-30 16:54:23 IST,2018-10-30,16:54:23,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,SB-525 $PFE $SGMO pipeline in #hemophilia now in Phase 2 according to Pfizer's updated pipeline list  https://t.co/7SgGmgC3xC,en,[],['https://www.pfizer.com/science/drug-product-pipeline'],[],2,4,11,['hemophilia'],"['pfe', 'sgmo']",https://twitter.com/Biotech2050/status/1057231736864731136,False,,0,,,,,,,,[],,,,
1054703258449702944,1054703258449702944,2018-10-23 17:27:06 IST,2018-10-23,17:27:06,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,Bain Capital teams with Pfizer to create new #neuroscience-focused company   https://t.co/S2egh5UMHA  $SGMO + $PFE collaborating for the dev. and  commerc. of therapeutics using our zinc finger protein  transcription factors #ALS and #FTLD linked to mutations  of the C9ORF72 gene,en,[],['https://www.cnbc.com/2018/10/23/bain-capital-teams-with-pfizer-to-create-new-neuroscience-focused-company.html?__source=twitter|main'],[],0,5,13,"['neuroscience', 'als', 'ftld']","['sgmo', 'pfe']",https://twitter.com/_B_I_O_T_E_C_H_/status/1054703258449702944,False,,0,,,,,,,,[],,,,
1053277144837709825,1053277144837709825,2018-10-19 19:00:14 IST,2018-10-19,19:00:14,+0530,475309726,tradestation,TradeStation,,"What do big pharmas like Merck ($MRK), Pfizer ($PFE), Roche ($RHBBY), and Novartis ($NVS) have in common? They all have PDUFA dates coming up in Q4 ‚Äî which can (but doesn‚Äôt always) spell greater volatility. Take a look.  https://t.co/rPl9AIhewz",en,[],[],['https://pbs.twimg.com/media/Dp39-tjWoAEc7XA.jpg'],1,4,45,[],[],https://twitter.com/TradeStation/status/1053277144837709825,False,,1,https://pbs.twimg.com/media/Dp39-tjWoAEc7XA.jpg,,,,,,,[],,,,
1052580221080227840,1052580221080227840,2018-10-17 20:50:55 IST,2018-10-17,20:50:55,+0530,93687723,berthacoombs,Bertha Coombs,,SCOOP via @BerkleyJr: Drug giant Pfizer offers early retirement ahead of layoffs in memo to employees  $PFE  https://t.co/MIY60O4zJ6,en,"[{'screen_name': 'berkleyjr', 'name': 'brian k. berkley jr.', 'id': '507166150'}]",['https://cnb.cx/2EsbUAn'],[],2,5,6,[],['pfe'],https://twitter.com/berthacoombs/status/1052580221080227840,False,,0,,,,,,,,[],,,,
1052494878846922753,1052494878846922753,2018-10-17 15:11:48 IST,2018-10-17,15:11:48,+0530,102754598,johncendpts,John Carroll,,Pfizer bags an FDA OK for PARP player talazoparib ‚Äî now the hard part begins $PFE $AZN $MRK $CLVS $TSRO  https://t.co/WooxDhpMgq,de,[],['https://endpts.com/pfizer-bags-an-fda-ok-for-parp-player-talazoparib-now-the-hard-part-begins/'],[],2,2,9,[],"['pfe', 'azn', 'mrk', 'clvs', 'tsro']",https://twitter.com/JohnCendpts/status/1052494878846922753,False,,0,,,,,,,,[],,,,
1049761253663678466,1049761253663678466,2018-10-10 02:09:21 IST,2018-10-10,02:09:21,+0530,102754598,johncendpts,John Carroll,,#2 $pfe New Pfizer CEO Albert Bourla shakes up the top team that will now lead the pharma giant ‚Äî and there‚Äôs a chief digital officer coming on board  https://t.co/MK4WNOGea3,en,[],['https://endpts.com/pfizer-shakes-up-the-top-team-that-will-now-lead-the-pharma-giant-under-albert-bourla/'],[],0,7,11,[],['pfe'],https://twitter.com/JohnCendpts/status/1049761253663678466,False,,0,,,,,,,,[],,,,
1049158284484141056,1049011244554842112,2018-10-08 10:13:22 IST,2018-10-08,10:13:22,+0530,3943627812,forever_dna,Forever DNA,,@semodough Again with $SRPT &amp; $PFE . Isn't Pfizer getting tired yet of going to every DMD meeting as the really little dog w/ the great big market cap?,en,[],[],[],2,0,14,[],"['srpt', 'pfe']",https://twitter.com/Forever_DNA/status/1049158284484141056,False,,0,,,,,,,,"[{'screen_name': 'semodough', 'name': 'dough', 'id': '3426014292'}]",,,,
1047636566510899203,1024454843665182720,2018-10-04 05:26:36 IST,2018-10-04,05:26:36,+0530,906328017986899968,the_chart_life,"Ian McMillan, CMT",,$PFE Pfizer ...Hot damn.  https://t.co/cF1tF9scWw,de,[],[],['https://pbs.twimg.com/media/Donz5tkX0AUGDDv.jpg'],0,0,4,[],['pfe'],https://twitter.com/the_chart_life/status/1047636566510899203,False,,1,https://pbs.twimg.com/media/Donz5tkX0AUGDDv.jpg,,,,,,,[],,,,
1047551702931595264,1047551702931595264,2018-10-03 23:49:23 IST,2018-10-03,23:49:23,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,In 3 years time there will be gene editing In #Hemophilia  $SGMO CEO remarks a few minutes ago. Sangamo's next steps just disclosed in front of $PFE @pfizer,en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}]",[],[],0,9,16,['hemophilia'],"['sgmo', 'pfe']",https://twitter.com/Biotech2050/status/1047551702931595264,False,,0,,,,,,,,[],,,,
1046788971706175489,1046788971706175489,2018-10-01 21:18:33 IST,2018-10-01,21:18:33,+0530,15110357,reutersbiz,Reuters Business,,"JUST IN: Pfizer shares hit over 17-year high after Albert Bourla appointed CEO, last up about 1 percent $PFE  https://t.co/mV3b2tmeeL",en,[],[],['https://pbs.twimg.com/media/DobxBZfU8AAhfap.jpg'],0,8,14,[],['pfe'],https://twitter.com/ReutersBiz/status/1046788971706175489,False,,1,https://pbs.twimg.com/media/DobxBZfU8AAhfap.jpg,,,,,,,[],,,,
1046713463182163968,1046713463182163968,2018-10-01 16:18:31 IST,2018-10-01,16:18:31,+0530,540233480,pfizer_news,Pfizer Inc.,,"Pfizer announces CEO succession plan: Dr. Albert Bourla to succeed Ian Read as CEO, effective January 1, 2019  https://t.co/8ZCxJKaQvA $PFE  https://t.co/2v34nGeaDB",en,[],['https://on.pfizer.com/2OWQdci'],['https://pbs.twimg.com/media/DoasWO5XkAAxYBg.jpg'],0,9,26,[],['pfe'],https://twitter.com/pfizer_news/status/1046713463182163968,False,,1,https://pbs.twimg.com/media/DoasWO5XkAAxYBg.jpg,,,,,,,[],,,,
1045624655887896576,1045624655887896576,2018-09-28 16:11:59 IST,2018-09-28,16:11:59,+0530,102754598,johncendpts,John Carroll,,Pfizer nabs fast OK for a new frontline lung cancer drug as pharma giant shows off its new R&amp;D strategy $PFE  https://t.co/SvU4htYs8h,en,[],['https://endpts.com/pfizer-nabs-fast-ok-for-a-new-frontline-lung-cancer-drug-as-pharma-giant-shows-off-its-new-rd-strategy/'],[],0,3,8,[],['pfe'],https://twitter.com/JohnCendpts/status/1045624655887896576,False,,0,,,,,,,,[],,,,
1045558345942339584,1045514288293539841,2018-09-28 11:48:29 IST,2018-09-28,11:48:29,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,@_B_I_O_T_E_C_H_ @SangamoTx Great catch! Wow!  Tell us $SGMO @SangamoTx why is #hemophilia B pipeline not listed with proprietary programs? Have you done another deal with @Pfizer $PFE?,en,"[{'screen_name': 'sangamotx', 'name': 'sangamo therapeutics', 'id': '809083633671643136'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}]",[],[],1,1,9,['hemophilia'],"['sgmo', 'pfe']",https://twitter.com/Biotech2050/status/1045558345942339584,False,,0,,,,,,,,"[{'screen_name': '_B_I_O_T_E_C_H_', 'name': 'üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑', 'id': '4859660471'}, {'screen_name': 'SangamoTx', 'name': 'Sangamo Therapeutics', 'id': '809083633671643136'}]",,,,
1044585185822466049,1044585185822466049,2018-09-25 19:21:30 IST,2018-09-25,19:21:30,+0530,57124794,annaedney,Anna Edney,,"Pfizer wants to meet rivals J&amp;J, Amgen and Roche at the flagpole after school  https://t.co/kkYfJ6ZHou via @JaredSHopkins $PFE $AMGN $JNJ $ROG",en,"[{'screen_name': 'jaredshopkins', 'name': 'jared s. hopkins', 'id': '42814585'}]",['https://www.bloomberg.com/news/articles/2018-09-25/brand-name-drugmakers-turn-on-each-other-in-fight-for-new-market'],[],2,8,12,[],"['pfe', 'amgn', 'jnj', 'rog']",https://twitter.com/annaedney/status/1044585185822466049,False,,0,,,,,,,,[],,,,
1037208434389737473,1037208434389737473,2018-09-05 10:48:55 IST,2018-09-05,10:48:55,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,$5B debt offering by $PFE @pfizer To partly fund a major acquisition? Which company could it be should the funding be required for acquisitions?  Wonder if they will be listening to $SGMO presentation today.  https://t.co/vtqD0ET0KU,en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}]",['https://twitter.com/odibro/status/1037204872268009472?s=19'],[],2,7,18,[],"['pfe', 'sgmo']",https://twitter.com/Biotech2050/status/1037208434389737473,False,https://twitter.com/odibro/status/1037204872268009472?s=19,0,,,,,,,,[],,,,
1035156494789033984,1035156494789033984,2018-08-30 18:55:15 IST,2018-08-30,18:55:15,+0530,57921721,beauregard2,beauregard,,"$SRPT $PFE The terminated drug was Pfizer's myostatin blocker. I've been criticizing the myostatin-blocking approach for years now. It was a dangerous idea from the start. The body produces myostatin for a reason, and it doesn't cause DMD.",en,[],[],[],0,1,14,[],"['srpt', 'pfe']",https://twitter.com/beauregard2/status/1035156494789033984,False,,0,,,,,,,,[],,,,
1035136796282290176,1035136796282290176,2018-08-30 17:36:58 IST,2018-08-30,17:36:58,+0530,223589965,gantosj,Joe,,"$PFE Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne Muscular Dystrophy. The Phase 2 study (B5161002), did not meet its primary efficacy endpoint. Still running the GT study AAV9  PF-06939926 $SRPT is the leader  https://t.co/jSsLfXB0NM",en,[],['https://www.businesswire.com/news/home/20180830005364/en/Pfizer-Terminates-Domagrozumab-PF-06252616-Clinical-Studies-Treatment'],[],1,7,37,[],"['pfe', 'srpt']",https://twitter.com/GantosJ/status/1035136796282290176,False,,0,,,,,,,,[],,,,
1034890738822205441,1034890738822205441,2018-08-30 01:19:14 IST,2018-08-30,01:19:14,+0530,1370906497,maisacorp,MAISA,,"$PTLA could be a takeout candidate. $JNJ might be a buyer. Other candidates include  Pfizer $PFE, Merck $MRK and Bristol-Myers Squibb $BMY.",en,[],[],[],0,1,7,[],"['ptla', 'jnj', 'pfe', 'mrk', 'bmy']",https://twitter.com/MaisaCorp/status/1034890738822205441,False,,0,,,,,,,,[],,,,
1034044760749760512,1034044760749760512,2018-08-27 17:17:37 IST,2018-08-27,17:17:37,+0530,44438256,matthewherper,Matthew Herper,,Pfizer Drug Reduces Death Rate In Patients With Hearts Damaged By Protein Clumps $PFE RALNY $EIDX  https://t.co/mXm4g8fwTg,en,[],['https://www.forbes.com/sites/matthewherper/2018/08/27/pfizer-drug-reduces-death-rate-in-patients-with-hearts-damaged-by-protein-clumps/#2a658e73204c'],[],2,3,8,[],"['pfe', 'eidx']",https://twitter.com/matthewherper/status/1034044760749760512,False,,0,,,,,,,,[],,,,
